International Journal of Progressive Sciences and Technologies (IJPS
ISSN: 2509-0119.

Vol. 39 No. 2 July 2023, pp. 101-132

Management of Multiple Sclerosis

Clinical Review

Maged Naser[1], Mohamed M. Nasr[2], Lamia H. Shehata[3]

[1] Mazahmiya Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Ob/Gyn,

[2] King Fahd Hospital, Ministry of Health, Kingdom of Saudi Arabia, Department of Surgery, Consultant Endoscopic Surgery,

[3] Department of Radiology, Care National Hospital, KSA of Radiology

Abstract – Multiple sclerosis (MS) is an immune system demyelinating and neurodegenerative disease of the central nervous system, and the main source of non-traumatic neurological disability in young adults. Successful management requires a complex way to deal with control acute attacks, manage progressive declining, and remediate bothersome or handicapping side effects related with this disease. Striking advances in treatment of all types of MS, and particularly for relapsing disease, have well changed the long-term outlook for some patients. There likewise has been a calculated change in figuring out the immune pathology of MS, away from a simply T-cell interceded model to acknowledgment that B cells play a vital part in pathogenesis. The rise of higher-efficacy drugs requiring less frequent administration have made these favoured choices with regards to tolerability and adherence. Numerous specialists currently suggest utilization of these as first-line treatment for some patients with early disease, before long-lasting handicap is evident.

Keywords – Multiple Sclerosis, B cell Therapy, Treatment of Multiple Sclerosis.

I. INTRODUCTION

The immune system disease multiple sclerosis (MS) is the main source of non-traumatic neurological disability emerging in youthful adults. [1,2] MS is portrayed by two pathological hallmarks: 1) inflammation with demyelination, and 2) astroglial proliferation (gliosis) and neurodegeneration. Tissue damage in MS is limited to the central nervous system (CNS), sparing the peripheral sensory system. Clinically, MS can follow two ways: relapsing or progressive. Most usually, beginning is a relapsing type of MS (RMS), appeared as discrete episodes of neurological dysfunction followed by partial, complete, or no remission. Over the long-term, relapses as a rule decline in frequency yet a steady deteriorating frequently happens, bringing about continuous movement (named secondary progressive MS [SPMS]). Under 10% of patients with MS experience progression from beginning, a classification named primary moderate MS (PPMS).[3] Regardless of these distinctions, all clinical types of MS seem to reflect a similar underlying disease process. Furthermore, in spite of the fact that inflammation is normally connected with relapses, and neurodegeneration with progression, it is currently perceived that the two pathologies are available in essentially all patients across the whole disease continuum.

MS is a worldwide issue, and its prevalence is on the rise.[4] The predominance is most noteworthy in North America, Western Europe and Australasia (>100 cases per 100,000 populace), and least in nations based on the equator (<30 cases per 100,000 population).4 In the US, a new report assessed that almost 1 million people are impacted. In RMS, women are impacted almost multiple times more frequently than men and the mean period of beginning is ~30 years, while in PPMS the rates of people impacted are similar and the mean period of beginning is ~40 years. [5-7]. The improvement of progressively compelling treatments for RMS, and somewhat effective treatment for PPMS and SPMS, addresses a significant achievement that has decisively further developed possibilities for lives free from handicap. For patients with RMS, the interim to improvement of SPMS was generally assessed at around 19 years after beginning yet in the treatment period has been stretched considerably. On exceptionally effective treatment

Corresponding Author: Maged Naser

relapses are extraordinarily diminished or wiped out. Nonetheless, control of RMS has uncovered a relapses independent "silent" progression that was recently obscured by assaults and remissions in RMS.[8,9] This acknowledgment has likewise prompted a rising dependence on profoundly effective treatments right off the bat over MS to control the both relapses and progression maximally. In this review we sum up recent advances in MS treatment and speculate on future directions.

1-Diagnosis

1.1 Clinical Manifestations

MS symptoms vary as per location and severity of lesions happening inside the CNS. Clinical components of RMS could present intensely or subacutely over hours to days, at times followed by progressive unconstrained reductions over weeks to months. Alternately, PPMS is portrayed by slowly progressive symptoms from onset. Table (1) sums up normal clinical and laboratory features of MS. Symptoms might be extreme at beginning or start insidiously, now and again unnoticed for months or years. When the patient seeks for clinical attention, and if MS is thought, brief reference to a specialist is indicated.

Table (1) Diagnosis of Multiple Sclerosis [10]

<table>
<tr><th>Symptoms</th><th>Magnetic Resonance Imaging (MRI)</th></tr>
<tr><td rowspan="5">Sensory loss or paresthesias (tingling)
Unilateral painful visual loss (optic neuritis)
Limb weakness (hyperreflexia, Babinski sign)
Facial weakness resembling Bell’s palsy
Visual blurring due to diplopia
Ataxia
Vertigo
Paroxysmal symptoms
Lhermitte’s symptom (electric shock-like sensations evoked by neck flexion)
Trigeminal neuralgia, hemifacial spasm, and glossopharyngeal neuralgia
Facial myokymia (rapid flickering contractions of the facial muscles l
Heat sensitivity
Bladder dysfunction
Pain
Cognitive dysfunction, usually mild, “brain fog”, difficulty with multitasking.
Sexual dysfunction
Fatigue</td><td>Multiple Lesions
White matter
Cerebral hemispheres, brainstem, spinal cord
Recent lesions enhance with gadolinium
Lesions perpendicular toventricular surface and juxtacortical</td></tr>
<tr><td>Cerebrospinal Fluid</td></tr>
<tr><td>Oligoclonal immunoglobulin
Modest inflammation (mononuclear cells)</td></tr>
<tr><td>Evoked Potentials</td></tr>
<tr><td>Detect conduction delay in visual, auditory, and sensory pathways</td></tr>
<tr><td colspan="2">Uncommon Symptoms (Red Flags)</td></tr>
<tr><td colspan="2">Seizure
Dementia
Movement disorder</td></tr>
</table>

Finding requires objective proof of inflammatory CNS injury and frequently extra details of spread of the disease cycle "in space and time", for example influencing more than one CNS location with advancement after some time (Table 2). Symptoms should keep going for >24 hours and happen as distinct episodes isolated by at least one month. The main tests used to support diagnosis are magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) analysis.

Table (2) Criteria for diagnosis of multiple sclerosis in patients with an attack at onset [11]

≥2 attacks; objective clinical evidence of ≥2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack
≥2attacks; objective clinical evidence of 1lesion *Dissemination in space, demonstrated by:* ≥1 T2 lesion on MRI in at least 2 out of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) OR Await a further clinical attack implicating a different CNS site
1attack; objective clinical evidence of ≥2lesions *Dissemination in time, demonstrated by:* Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at any time OR A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of its timing with reference to a baseline scan OR Await a second clinical attack
1attack; objective clinical evidence of 1 lesion (clinically isolated syndrome) *Dissemination in space and time, demonstrated by:* *For dissemination in space* ≥1T2 lesion in at least 2 out of 4 MS-typical regions of the CNS (periventricular, juxtacortical, infratentorial, or spinal cord) OR Await a second clinical attack implicating a different CNS site AND *For dissemination in time* Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at any time OR A new T2 and/or gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of itstiming with reference to a baseline scan OR Await a second clinical attack

Criteria for diagnosis of multiple sclerosis in patients with a disease course characterized by progression from onset (primary progressive multiple sclerosis) Insidious neurologic progression suggestive of primary progressive multiple sclerosis *1 year of disease progression (retrospectively or prospectively determined) AND 2 out of the 3 following criteria:*

a. Evidence for dissemination in space in the brain based on ≥1 T2+ lesions in the MS-characteristic periventricular, juxtacortical, or infratentorial regions

b. Evidence for dissemination in space in the spinal cord based on ≥2 T2+ lesions in the cord

C. Positive cerebrospinal fluid (isoelectric focusing evidence of oligoclonal bands and/or elevated IgG index

In many patients abnormal MRI is observed, Spillage of intravenous gadolinium is brought about by breakdown in the blood-cerebrum obstruction that happens from the get-go in the improvement of a MS sore and is a marker of intense irritation. Gadolinium improvement normally continues for 90% of MS patients. Raised intrathecal immunizer creation can likewise be utilized to satisfy "dispersal in time" standards in patients giving their most memorable clinical appearance of MS. Albeit delicate, raised CSF neutralizer creation isn't explicit for MS, and furthermore happens with CNS diseases. In excess of 50 cells/mm3 are uncommon in MS, and polymorphonuclear leukocytes, eosinophils or a uniquely raised all out-protein level ought to raise doubt about the determination .Other valuable tests remember evoked possibilities to evaluate nerve conduction for CNS pathways, and retinal imaging by optical cognizance tomography.[12]

2. MS Treatment

2.1 Drug Treatment

Summary of drug administration, dosing, results of pivotal clinical trials, adverse events and safety monitoring for interferons and glatiramer acetate.

Table (3) Summary of Approved Disease-Modifying Therapies for Multiple Sclerosis

Drug name	Mechanism of action	Indication n	Route of and frequency of administration n	Pivotal efficacy data	Common adverse events
Highly effective					
Ocrelizumab[13,14]	Anti-CD20 mAb	RMS and PPMS (1st line)	IV infusion, every 6 months	RMS: Relative reduction in ARR compared with IFN β-la:47% PPMS: Relative reduction in 12-week CDP compared with placebo: 24%	RMS: Infusion-related reaction, nasopharyngitis, upper respiratory tract infection, headache, and urinary tract infection PPMS: Infusion-related reaction, upper respiratory tract infection, and oral herpes infection
Ofatumumab[15]	Anti-CD20 mAb	RMS (1st line)	SC injection, every 4 weeks	Relative reduction in ARR compared with teriflunomide: 54%	Injection-related reaction, nasopharyngitis, headache, upper respiratory tract infection, and urinary tract infection
Natalizumab[16]	α4β1 integrin inhibitor	RRMS (2nd line)	IV infusion, every 4 weeks	Relative reduction in ARR compared with placebo: 68% Relative reduction in sustained disease progression compared with placebo: 42%	Fatigue and allergic reaction
Alemtuzumab[17-19]	Anti-CD52 mAb	RMS (1st line)	IV infusion, once daily	Relative reduction in ARR compared	Headache, rash, nausea, and pyrexia

				with placebo: 49–69%	
Mitoxantrone[20]	DNA intercalator	RMS, SPMS (2nd or 3rd line)	IV infusion, every month or 3 months	Relative reduction in relapses compared with placebo: 61%	Dose-related cardiomyopathy, promyelocytic leukaemia
Moderately effective					
FingolimodM[21,22]	Sphingosine-1- phosphate inhibitor	RMS (2nd line)	Oral, once daily	Relative reduction in ARR compared with placebo: 48–60%	Bradycardia, atrioventricular conduction block, macular oedema, elevated liver-enzyme levels, and mild hypertension
Siponimod[23]	Sphingosine 1-phosphate receptor modulator	CIS, RMS, active SPMS (1st Line)	Oral, once daily	Relative reduction in 12-week CDP compared with placebo: 21%	Headache, nasopharyngitis, urinary tract infection, and falls
Ozanimod[24,25]	Sphingosine 1-phosphate receptor modulator	CIS, RMS, active SPMS	Oral, once daily	Relative reduction in ARR compared with placebo: 48%	Headache and elevated liver aminotransferase
Dimethyl fumarate and diroximel Fumarate[26,27]	Nuclear factor (erythroid-derived 2)-like 2 pathway inhibitors	RMS (1st line)	Oral, twice daily	Relative reduction in ARR compared with placebo: 48–53%	Flushing, diarrhoea, nausea, upper abdominal pain, decreased lymphocyte counts, and elevated liver aminotransferase
Cladribine[28]	Not fully known	RMS (2nd or 3rd line)	Oral, 4–5 days over 2-week treatment courses	Relative reduction in ARR compared with placebo: 55–58%	Headache, lymphocytopenia, nasopharyngitis, upper respiratory tract infection, and nausea

Modestly effective					
Teriflunomide[29]	Dihydroorotate dehydrogenase e inhibitor	RMS (1st line)	Oral, once daily	Relative reduction in ARR compared with placebo: 32–36%	Nasopharyngitis, headache, diarrhoea, and alanine aminotransferase e increase
Glatiramer Acetate[30]	Not fully known	RMS (1st line)	SC injection, once daily or 3 times weekly	Relative reduction in ARR compared with placebo: 29%	Injection-site reactions
IFN β-la (Rebif)[31]	Not fully known	CIS and RMS (1st line)	SC injection, 3 times weekly	Relative reduction in ARR compared with placebo: 33%	Injection-site inflammation, flu-like symptoms, rhinitis, and headache
IFN β-la (Avonex)[32]	Not fully known	CIS and RMS (1st line)	IM injection, once weekly	Relative reduction in 24-week CDP compared with placebo: 37%	Flu-like symptoms, muscle aches, asthenia, chills, and fever
PeglFN β-la (Plegridy)[33]	Not fully known	CIS and RMS (1st line)	SC injection, every 2 weeks	Relative reduction in ARR compared with placebo: 39%	Injection-site erythema, influenza-like illness, pyrexia, and headache
IFN β-lb (Betaseron)[34]	Not fully known	CIS and RMS (1st line)	SC injection, every other day	Relative reduction in ARR compared with placebo: 31%	Lymphopenia, flu-like symptoms, and injection-site reactions

ARR, annualized relapse rate; CDP, confirmed disability progression; CIS, clinically isolated syndrome; IFN β−1a, interferon beta 1a; IM, intramuscular; IV, intravenous; mAb, monoclonal antibody; PPMS, primary progressive multiple sclerosis; RMS, relapsing forms of multiple sclerosis; SC, subcutaneous; SPMS, secondary progressive multiple sclerosis.

2.2 Cell Treatment Approaches of the Multiple Sclerosis

2.2.1. Hematopoietic stem cells

Hematopoietic stem cells (HSCs) expressing CD34+CD38-CD90+CD45RA-CD49f+ are immature pluripotent cells that can develop into a wide range of blood cells of both the lymphoid and myeloid lineages [35]. Thus, the point of HSC transplantation (HSCT) is to give a one-time treatment that gives long-lasting disease adjustment. For sure, following immunoablation with immunosuppressive medications, which are utilized to dispose of all pathogenic autoreactive lymphocytes and decrease irritation in the CNS, patients are treated with HSCT to help hematopoiesis, consequently re-establishing the immune system and re-establishing self-tolerance. HSCs can be segregated from the bone marrow or peripheral blood after preparation with drugs, for example, cyclophosphamide or potentially granulocyte-colony stimulated factor (G-CSF), that upgrade expansion of HSCs furthermore, drive them from the bone marrow into the peripheral blood [36,37]. The accompanying suggestions are made with respect to collection of HSCs, as per the handbook of the European Culture for Blood and Marrow Transplantation (EBMT) [38]. Bone marrow is the favored source of HSCs. Different bone marrow aspirations of 5 mL each, with a limit of 20 mL/kg giver bodyweight, are recommended to get a target dose of 3 × 106 CD34+ cells/kg. Nonetheless, peripheral blood stem cell collection is inclined toward, as it is viewed as less unpleasant for the patient and prompts quicker engraftment and hematologic reconstitution. For this, the immune target is 2 × 106 CD34+ cells/kg collected by leukapheresis. Be that as it may, higher amounts of cells are gone for the aimed, 5 × 106 CD34+ cells/kg, bringing about quicker neutrophil and platelet recuperation, and reduced hospitalization, blood transfusion and antibiotic treatment. Autoimmune diseases, like MS, are generally treated with autologous HSCT (AHSCT) for safety reasons [39].

At the clinical level, AHSCT is a rescue treatment in young patients with RRMS who have low or medium handicap grades because of aggressive inflammatory disease course and in whom other profoundly useful therapies have failed [40,41,42]. One review showed that the extent of patients with MS who accomplished no evidence of disease activity (NEDA) after AHSCT was exceptionally high contrasted with patients who got approved DMTs [41]. In a new meta-analysis [43], 83% of patients who got AHSCT showed NEDA following 2 years and 67% kept up with NEDA following 5 years. The primary risk related with AHSCT is treatment-related mortality, yet that this hazard has decreased from 3.6% to 0.3% in patients transplanted after 2005 [41]. A new report from the Italian bone marrow transplantation (BMT)- MS Study Gathering revealed that there were no deaths in patients relocated after 2007 [44]. In a cohort of 210 MS patients with a median baseline extended disability status scale (EDSS) of 6.0, a high extent had a durable disease reduction up to 5-10 years after the methodology; a portion of these patients had progressive MS [44]. The Swedish Leading group of health and welfare considers AHSCT as a legitimate treatment choice for patients with active MS [42,45] and a few agreement suggestions for the utilization of AHSCT in MS have been distributed in the past few years [39,46,47,48]. In any case, for patients with extremely progressed MS and elevated degrees of disability, HSCT can neither opposite nor stop the progression of the disease [49] and, thusly, isn't suggested.

As of not long ago, most studies on AHSCT were observational or prospective single-arm clinical preliminaries [50,51,52,53,54,55]. In one randomized controlled preliminary, the researchers contrasted AHSCT and treatment with mitoxantrone, which is seldom used to treat MS today [51]. The MS International Stem Cell Transplantation (MIST)-preliminary (NCT00273364) showed the predominance of AHSCT versus DMTs as far as the chance to disease progression [56]. All the more as of late, an observational cohort study on compared outcomes after treatment with alemtuzumab and AHSCT and found that the possibility keeping up with NEDA was altogether higher in the AHSCT-treated group [57]. Several clinical preliminaries, contrasting the impacts of AHSCT and high viability DMTs in patients with active RRMS, are progressing (Table 1). These incorporate the BEAT-MS (NCT04047628), RAM- MS (NCT03477500) and STAR-MS (ISRCTN88667898) [40]. These preliminaries will decide the similar adequacy of AHSCT and right now accessible and profoundly effacious DMTs, for example, alemtuzumab, natalizumab and ocrelizumab.

The immunological impacts that underlie the extreme shift in the disease course of MS following AHSCT are just to some extent comprehended. It has been observed that natural killer (NK) cells, CD8+ T-cell and B cells repopulate inside the space of weeks to months, while the reconstitution of CD4+ Lymphocytes can require as long as 2 years

[62,63,64,65,65,66,67,68]. T-cells created after AHSCT under selection and development in the thymus and show a more different profile with new White blood cell receptor (TCR) clones contrasted and the predominant clones that were available before AHSCT and that were generally eliminated by the immunoablative treatment before the transplantation. It has been shown that over 90% of pre-existing T-cells clones are taken out from the peripheral blood and the CSF and replaced with clonotypes from the graft [58]. This is prevalently the case for CD4+ T-cells and, to a lot lesser degree, for CD8+ White blood cells [58,59,60]. Whether this restricted exhaustion of CD8+ T-cells is related with relapses or disease progression after AHSCT. In this unique situation, mucosal-associated invariant T (MAIT) cells, a novel CD161highCD8+ cell populace starting in the gut mucosa yet communicating the CNS-homing receptor CCR6, have been found in lesions in the brains of patients with MS [61]. The fast reconstitution of NK cells adds to differentiate into Th17 cell reconstitution [62]; immune is further additionally improved by the development of T regs [61]. In any case, myelin-explicit Tcells are as yet found after AHSCT, yet with an unequivocally diminished ability to separate into Th17 cells contrasted with their capacity earlier with the transplantation [63].Strangely, changes in the gene profiles of CD4+ and CD8+ T cells have been depicted, which recommends that the gene expression standardizes in CD8+ T cells after AHSCT expression [64]. Moreover, albeit all B cells, with the exception of plasma cells, are exhausted during HSCT, one review exhibited that oligoclonal groups endure after the transplantation, which proposes that immunoglobulin-delivering cells are not drained or are deficiently exhausted in the CNS [49]. This perception has been tested by Larsson et al. [65], who showed that intrathecal immunoglobulin creation and neurofilament light levels were lower after HSCT treatment and further decreased after some time. While contrasts in understanding qualities, for example, disease duration, disease type, and disease heterogeneity, or therapy related factors like the conditioning regimen, may underly the noticed disparities, studies including bigger accomplices along with researching the components of B cell reconstitution after HSCT are required. All in all, HSCT can be a treatment choice in select young patients with aggressive RRMS who failed to answer DMTs [39,65,66]. Immunological changes that happen after HSCT in MS are reminiscent of long -term induction of immune tolerance. Until now, no cell biomarkers have been distinguished that can predict which patients will benefit most from this strategy.

2.2.2 Mesenchymal Stromal Cells

Mesenchymal stromal cells (MSCs) are multipotent cells that have the capacity of self-restoration; MSCs can separate into different tissues of mesodermal beginning, like osteocytes, chondrocytes and adipocytes, and other embryonic lineages. MSCs are described by the outflow of CD73, CD105 and CD90 and the absence of expression of hematopoietic markers (i.e., CD45, CD34 and HLA-DR) and vascular markers (i.e., CD31) markers [65,67]. Given their adult cell potency, MSCs are frequently called mesenchymal immature stem cells, in spite of the fact that they are all the more precisely called multipotent mesenchymal stromal cells. MSCs were first depicted during the 1960s by Friedenstein who separated them from rat bone marrow through their inherent adherence to plastic [69]. Presently, MSCs can be isolated from blood, bone marrow, skeletal muscle, fat tissue, synovial membranes, and other connective tissues. No matter what the disconnection system, amounts of MSC acquired from essential tissues are not adequate for any application in clinical settings. Subsequently, in vitro propagation is quite often expected to accomplish an adequate cell number for in vivo application. MSCs have produced extraordinary interest due to their remedial capacity to prompt a significant immunosuppressive and mitigating impact in vitro and in vivo [69]. The mechanisms by which MSCs apply their immunosuppressive impact are not totally perceived. It is believed that they change the immunosuppressive effect into an anti-inflammatory environment straight by paracrine signals and by several discharged soluble variables, for example, changing growth factor beta (TGF-β) [76], hepatocyte growth factor [70], indoleamine 2,3-dioxygenase (IDO) [71], nitric oxide [72], interleukin (IL)- 10 [73] and prostaglandin E2 [74], and through cell-to-cell contact by means of the inhibitory molecule programmed death 1 (PD-1) [75]. MSCs additionally work by implication through the recruitment of other regulatory frameworks that include antigen-presenting cells (APCs) [76] and T regs [77]. In any case, it is apparent that MSC-induced unresponsiveness misses the mark on selectivity. MSCs primarily influence the functions of T cells; for example, MSCs prompt a cell cycle arrest in anergic T cells or a cytokine profile shift in the Th1/Th2 balance towards the anti-inflammatory Th2 aggregate [78,79]. Besides, MSCs stifle the cytolytic impacts of cytotoxic White blood cells [80]. MSCs are likewise fit for repressing NK cells [78,79], B cells and APCs. Besides, MSCs have been accounted for to advance the development of strong CD4+CD25+ and CD8+ Tregs in vitro and in vivo [82,83].

A several stage I and II clinical preliminaries utilized MSCs got from allogeneic donors and assessed their impact on immune system diseases, including type 1 diabetes (T1D), rheumatoid joint pain (RA) and MS [84]. Since MSCs address just a small fraction (0.001-0.01%) of total nucleated cells in bone marrow and different tissues, it was compulsory for these studies that the MSCs were extended ex vivo from a small bone marrow aspirate under clinical-grade states to great numbers in (8-10 weeks) [85,86]. The vast majority of the revealed preliminaries, until this point, were uncontrolled open-label stage I studies incorporating patients with RR-MS, SP-MS, and PP-MS. A survey of preliminaries observed that MSCs were safe and tolerated by patients with MS [87]. Recently, a randomized placebo controlled stage II clinical preliminary found that five out of nine patients with MS who got an intravenous implantation of bone marrow-determined MSCs had a pattern to bring down cumulative numbers of gadolinium-enhancing lesions at a half year following infusion, as shown by magnetic resonance imaging (MRI) [88]. In any case, there was no significant decrease in the frequency of Th1 cells in the peripheral blood of patients treated with MSCs. MSCs are probably going to elevate neuroprotection notwithstanding their immunomodulatory characteristics [89,90,91]. To be sure, MSCs could advance endogenous repair by recruiting local neural cells, perhaps through the discharge of neurotrophic factors, in this way driving neurogenesis and remyelination [97,98]. The migratory potential and homing limit of these cells into the CNS actually should be explained. The clinical outcomes acquired involving MSC treatment in patients with MS affirmed the achievability and wellbeing safety of an in vivo use of MSC without major events. In any case, the migratory potential and homing limit of these cells into the CNS as well as the need clinically significant arise to be verified.

2.2.3 Regulatory T Cells

Tregs are a subset of CD4+ White blood cells that assume a significant part yet to be determined among immunity and tolerance. These cells are described by the expression of elevated degrees of IL-2 receptor α chain (IL-2Rα/CD25) and Fork head box P3 (FoxP3) [92,93], which is a master regulator that organizes the transcriptional hardware that initiates Treg-relevant genes, for example, il2ra (CD25) and ctla-4, by binding more than 1400 genes and going about as a transcriptional repressor and activator [94,95,96]. Its appearance is contrarily connected with the expression of IL-7R (CD127) [97]. FoxP3 T regs are for the most part partitioned into thymic-determined or naturally occurring Tregs (nTregs) and peripheral induced Tregs (iTregs), which have phenotypic and functional similitudes, as well as contrasts in stability and gene expression [98]. iTregs suppress inflammation at mucosal barriers, while the nTregs control immune responses to self-antigens [99]. An ongoing report characterized Tregs as a heterogenous mixture of cell sub-phenotypes with a high level of phenotypic complexity that reflected various conditions of maturation, differentiation and activation [100].Tregs are liable for limiting the harm to the body's own cells and tissues during persistent immunity and for keeping up tolerance. For this, Tregs act prevalently by suppressing, eliminating, or inactivating effector Tcells, including autoreactive T cells, in the periphery [101]. Subsequently, it is accepted that the interruption of Treg numbers as well as function gives free rein to self-responsive T cells, which might add to an expanded susceptibility to autoimmune diseases [102]. For sure, decreased numbers or the impaired functionability of Tregs have been related with the development of various autoimmune diseases , including MS [5], RA [103], T1D [104], psoriasis [105], myasthenia gravis [106] and immune system polyglandular condition type II [107]. Consequently, re-establishing tolerance in patients with these diseases could be the way to preventing autoimmunity. In such manner, adoptive cell transfer of Tregs has demonstrated to be successful in preventing autoimmunity [108,109] and graft versus-host disease (GVHD) [110,111], and in postponing graft rejection in preclinical animal models [112,113].

The suppressive collection of Tregs includes the secretion of immunosuppressive cytokines, for example, IL-10, IL-35 and TGF-β, and cytotoxic molecules, for example, granzyme B and perforin, as well as contact-dependent suppression (e.g., CTLA-4). Furthermore, Tregs can in an indirect way influence immune tolerance by suppression of APCs, like DCs (broadly checked in [114]). Besides, Tregs can transfer their suppressive action to conventional CD4+ White blood cells, which is named infectious tolerance [115]. They establish a local tolerogenic environment in which naïve Tcells convert into cells with a prompted Treg phenotype. These cells are liable for bystander suppression [116] on the grounds that they induce tolerance to cells engaged with the immune reaction without direct association. Consequently, adoptive cell transfer of Tregs may not need long term endurance of the administered cells and might be utilized to alleviate the immune system reaction in diseases where it is coordinated against various self-antigens.At present, there is a wide scope of Treg isolation and develop expansion protocols [117]. For example, effective isolation techniques with high

purity and effective extension protocols are expected to preserve the ideal cell attributes. In spite of the fact that Tregs are available all through the body, peripheral blood is the most usually utilized source of Tregs [118]. Notwithstanding, since Tregs contain just 5-7% of the CD4+ T cells that foster in the thymus and in the periphery [119], in vitro Treg expansion is obligatory following isolation of a profoundly pure Treg populace to create adequate cells for clinical application [117]. For example, effective isolation techniques with high purity and effective extension protocols are expected to preserve the ideal cell attributes. In spite of the fact that Tregs are available all through the body, peripheral blood is the most usually utilized source of Tregs [118]. Notwithstanding, since Tregs contain just 5-7% of the CD4+ T cells that foster in the thymus and in the periphery [120], in vitro Treg expansion is obligatory following isolation of a profoundly pure Treg populace to create adequate cells for clinical application [117]. Molecules including rapamycin [120,121,122], TGF-β [123] and all-trans retinoic acid (ATRA) [124,125], can be utilized to help Treg development and dependability, while preventing outgrowth of contaminating cells.

Positive preclinical results, a superior comprehension of the qualities of Tregs and the chance of getting enough of these cells have prepared for in excess of 50 dynamic and finished clinical studies. These studies have tried the safety, feasibility, and efficacy of adoptive cell transfer of Tregs with regards to both autoimmunity and transplantation [126]. As of late, likewise in MS, the clinical utilization of autologous CD4+CD25hiCD127−FoxP3+ Tregs was assessed in a stage I/IIa clinical review [127]. Altogether, studies on demonstrated the safety of the clinical utilization of ex vivo extended polyclonal Tregs and showed promising outcomes in the postponement and avoidance of graft rejection and in the treatment of autoimmune reactions [128].Be that as it may, the efficacy was not decisive and frequently just modest clinical reactions were gotten [129]. This could be, to some extent, because of the utilization of polyclonal Tregs which all in all focus on a wide mix of antigens that are not all connected with the disease, consequently possibly weakening the clinical impact. This is additionally affirmed in studies in mice exhibiting restricted impact of polyclonal Treg implantation in immunocompetent individuals except if big numbers of Tregs are directed [130,131]. Besides, the utilization of polyclonal Tregs could cause a transient risk of generalized immunosuppression [132]. Interestingly, Tregs isolated from pancreatic draining lymph nodes or pulsed with pancreatic islet antigen are fundamentally better at preventing disease beginning or cure immune system prone non-obese diabetic (NOD) mice contrasted and polyclonal Tregs [133,134,135,136,137]. In this manner, the utilization of antigen specific Tregs could assist with accomplishing improved clinical benefit in situations where the disease-causing antigen is known.

All the more remarkable Treg treatments could be designed by improving Treg antigen-specificity or functionality in view of the information acquired from T cells treatments in oncology [138]. Most endeavors include presenting transgenic TCRs or chimirec antigen receptors (CARs) into Tregs. In spite of the fact that TCRs and CARs are both synthetic receptors, transgenic TCRs keep up with the construction of the native TCR yet are intended for antigen selectivity and high affinity. CARs are engineered combination particles that express the antigen acknowledgment domain of a monoclonal immunizer and at least one TCR costimulatory signaling domains [114,119]. The two strategies have been tested in various animal models of autoimmune disease and transplantation [114]. In MS, pathogenic self-reactive T cells are targeted by murine transgenic Tregs which express an extracellular myelin basic protein (MBP) peptide-bound major histocompatibility complex (MHC) that is connected to an intracellular TCR-chain signaling domain. Accordingly, this interaction mirrors physiological TCR-signaling on Tregs, bringing about the activation of transgenic Tregs and in the subsequent emission of elevated degrees of anti-inflammatory cytokines [138]. Plus, adoptive move of transgenic Tregs had the choice to forestall and treat MBP-started experimental autoimmune encephalomyelitis (EAE) [139,140]. Extended human Tregs, transduced with an MBP-specific TCR, can suppress MBP-specific effector T cell really in vitro. These transduced cells improve disease in myelin oligodendrocyte glycoprotein (MOG)- induced EAE, which is demonstrative of the in vivo impact of bystander suppression interceded by soluble factors [141].Also, changing over antigen-specific effector T cells into Tregs through the overexpression of FoxP3 is being examined [142,143]. In one review, designed Tregs, overexpressing a MOG-specific CAR in trans with the murine FoxP3 gene, exhibited their suppressive capability in vitro [144]. Recently, restoration of Treg functionality in patients with MS was accounted for continuing in vitro development and MBP-specific TCR transduction of Tregs [145]. Further studies in Tregs as a cell treatment for MS, and other autoimmune diseases, will without a doubt give us fascinating new experiences.

2.2.4 Tolerogenic Dendritic Cells

DCs are the most professional APCs and are the sentinels of our immune system. They capture and process exogenous antigens and self-antigens in peripheral tissues [146,147,148] and present them to other immune cells after migration to the secondary lymphoid organs [146,149]. Hence, DCs stimulate naïve T cells, effector Lymphocytes, memory Lymphocytes and B cells. In doing as such, DCs bridge the innate and adaptive safe immune systems [150] and assume a significant part yet to be determined among immune and tolerance [151,152]. In patients with MS, DCs are richly present in mind sores, and show a favorable to provocative state with a modified aggregate or potentially capability contrasted and sound controls [153]. In particular, the DCs of patients with MS show upregulated levels of activation markers, like CD86, CD80 and HLA-DR, and fail to upregulate programmed death ligand 1 (PD-L1) [154,155,156] contrasted with their healthy counterparts. In addition, DCs from patients with MS emit more elevated levels of immune stimulatory cytokines, including IL-12p70, IL-18 and IL-23 [153,157,158], assessing the consequences for animal models of autoimmune disease will be essential before these cells can demonstrate their worth in phase I clinical preliminaries in humans.

2.2.4 Myeloid-Determined Suppressor Cells

MDSCs are innate immune cells from the myeloid linage and are significant for establishing an immunosuppressive climate in tumors. contrasted and DCs from healthy individuals. These discoveries highlight a possibly significant role for DCs in the pathogenesis of diseases, impacting the effector function of auto-reactive T and B cells [159].On the other hand, deploying the tolerogenic potential of DCs might actually a positive affect the balance among immunity and tolerance in MS. For this, DC function can be directly balanced in vivo before they can be utilized as an immunotherapeutic tool to treat MS [160], or tolerance prompting or tolerogenic DCs (tolDC) can be generated in vitro from peripheral blood CD14+ monocytes [161]. For the last later, a several immunosuppressive biologicals and drugs, including vitamin D3, cyclosporine, corticosteroids , TGF-β, and dexamethasone have been utilized. These factors have been exhibited to regulate the differentiation and function of DCs [162,163,164], as proven by the maturation -resistant phenotype, intermediate expression of co-stimulatory molecules, a shift towards anti-inflammatory cytokine production and a diminished ability to stimulate T cells reactions [165,166].The utilization of vitamin D3 is quite possibly of the most generally settled approach, as it has significant immune regulatory properties both invitro and in vivo [167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178,179,180,181,182] . These studies showed among others that myelin peptide-stacked to lDC, made with vitamin D3, prompted stable antigen-explicit hypo-responsiveness in myelin-reactive T cells from MS patients in vitro.

Furthermore, to ensure the efficiency and stability of antigen presentation by DCs, a several antigen loading systems have been developed to induce immune reactions [148]. These incorporate (1) the in vivo loading of antigens to circulating DCs in patients [183], (2) Different methods of in vitro loading of DCs with antigens [184,185,186,187,188,189,190,191] and (3) DC transfection with mRNA-encoding antigens [192, 193, 194, 195,196,197].Albeit the utilization of immune stimulatory DCs to reinforce immune reactions against malignant growth and infectious diseases has been comprehensively portrayed in numerous clinical preliminaries [198,199,200,201], the utilization of tolDC as a therapy technique for autoimmune disorders is still in its infancy. A predetermined number of studies have taken advantage of the tolerogenic capacity of DCs to treat patients diagnosed to have T1D, RA, Crohn's disease, MS and Neuromyelitis optica (NMO) [202,203,204,205,206] In particular, in MS.

2.2.5 Other Immune Cells

1. **B Cells**

B cells play a pleiotropic job in the enlistment of immune responses. They add to immunity through the production of antibodies, antigen presentation to T cells and the secretion of cytokines. There are various subsets of B cells. For example, early lineage CD20+CD79+CD27+ B cells function essentially as APCs expressing MHC and costimulatory molecules subsequently supporting T cell-mediated cell reactions, though late lineage CD138+ mature plasma cells and CD38+ plasmablasts secrete antibodies, including auto-antibodies, connected with the humoral reaction [207,208]. The role of B cells in autoimmunity has been underlined by the successful restorative impact of B cell consumption with anti-CD20 monoclonal antibodies [209]. Rituximab, a chimeric anti- CD20 monoclonal immune response, has shown to be profoundly beneficial for patients with specific autoimmune infections, including RA, MS and T1D. In any case,

while plasma cells and oligoclonal groups in the CSF stay unaffected by anti- CD20 treatments, B cell consumption aggravated by the symptoms in certain patients,

which recommends that B cells likewise play a defensive part in autoimmune pathology [210]. In this specific situation, IL-10-creating regulatory CD1d+CD5+ B cells were viewed as ready to downregulate the commencement of autoimmune diseases and the beginning or severity of EAE, collagen-induced arthritis, contact hypersensitivity and inflammatory bowel disease [211,212]. Subsequently, B cell-mediated regulation of the immune system might be of extraordinary interest for the improvement of new cell-based treatments for immunosuppression in the field of autoimmune diseases. Several preclinical examinations involved various types of B cells as preventive and remedial treatment in EAE, which gave preclinical proof to tolerance induction [213,214,215,216,217]. The receptive exchange of splenic IL-10-delivering CD1dhiCD5+ regulatory B cells, supposed B10 cells, isolated from mice treated with against CD20 monoclonal antibodies, achieved limited infection severity when the B10 cells were coordinated before EAE enlistment [218,219]. Recently, administration of B cells (B regs) additionally prompted oligodendrogenesis and remyelination in an EAE [220]. As far as anyone is concerned, no clinical preliminaries have utilized B cell-based treatment in patients with MS or other autoimmune system disease to date.

2. Natural Killer Cells

Natural Killer (NK) cells are innate cytotoxic lymphocytes got from CD34+ hematopoietic progenitor cells which are engaged with early defense systems [221,222,223]. Human NK cells can be distinguished by the molecular marker CD56 without any the expression of CD3, while the mix of the expression of CD56+ and CD3+ characterize a mixed population of NK-like T cell (NKT) and antigen-experienced Tcells [224]. CD56 bright NK cells are generally present in secondary lymphoid tissue, while large numbers of CD56 dim NK cells are found in the bone marrow, blood and spleen [221,225]. NK cells actuate apoptosis of their target cells by using granzyme B and perforin, and by emitting inflammatory cytokines, like IFN-γ, upon stimulation with IL-12 or different cytokines, which are delivered by monocytes, macrophages or DCs [221,222,223]. Recently, the generation of trained immunity, i.e., immune memory of the innate immune system, has been depicted [226] . In this point of view, comparable useful properties as the adaptive immunity system have been credited to NK cells, including the development of antigen-specific cells, the generation of enduring memory cells that can continue after experience with an antigen, and the conceivable induction of a boosted secondary recall reaction.

In MS, NK cells assume a double role since they have defensive and pathogenic properties, as confirmed by the disconnected outcomes got in EAE [224,225].This duality is illustrated by the way that daclizumab, a humanized ant-CD25 monoclonal antibody, diminishes the disease activity in various patients with MS, yet has provoked extreme CNS inflammation in 12 patients worldwide[227]. The gainful system of activity of daclizumab was intervened by the development of the CD56 bright NK cell populace, which prompted the killing of activated Tcells. Concerning expanded CNS autoimmunity then again, it has been speculated that the mechanisms included prompted a reduction in Tregs [228]. Worries about — possibly autoimmune system — hepatotoxicity brought about the withdrawal of daclizumab from the market in March 2018 [229,230,231].Though that NK cell-based immunotherapy shows promising outcomes in beginning phase clinical preliminaries in hematological malignancies and solid tumors [232], more fundamental research is required before NK cell-based treatments can be utilized in human clinical preliminaries in MS. This incorporates the distinguishing proof of a regulatory NK cell subset, the ideal strategies for cell seclusion, isolation and differentiation and the administration routine [233].

3. Natural Killer T Cells

A Tcell subset with regulatory properties that displays characteristic of NK cells has been recognized in mice and humans (widely checked on somewhere else [234,235,236]). These NKT cells are a subset of innate lymphocytes that perceive endogenous or exogenous glycolipids with regards to CD1d molecules expressed by APCs, like monocytes, DCs and myeloid-derived suppressor cells (MDSCs). Upon antigenic stimulation, NKT cells produce a variety of immunomodulatory cytokines, which enriches the cells with intense immunoregulatory properties. Regardless, different subtypes of NKT cells might have various impacts in the immune system [237]. Critically, NKT cells in MS were portrayed to act as both defensive and pathogenic lymphocytes [238]. The role of NKT cells in the pathophysiology of MS needs further explanation before they could be utilized as a cell-based treatment.

The role of NKT cells and their true capacity for modulation to increment tolerance towards self-antigens have been explored in vitro and in animal models of different autoimmune diseases [239,240]. Nonetheless, disabled NKT cell capability in patients with autoimmune diseases could hamper the clinical utilization of autologous NKT cells, except if in vitro control could change their capability. Also, NKT cells comprise under 1% of Tcells in the peripheral blood [241]. Thus, in vitro development is expected to accomplish an adequate cell number for in vivo application [241].Disregarding the way that NKT cell-based treatment has been investigated in the field of malignant growth research [237], there have been no studies in animal models of autoimmune diseases.

4. Myeloid-Derived Suppressor Cells

MDSCs are innate immune cells from the myeloid linage and are important for creating an immunosuppressive environment in tumors [242]. They play a protective role in autoimmune diseases through the inhibition of T cell-mediated immune responses [242]. Two large groups of cells have been described (extensively reviewed in [239,240,241]). In brief, granulocytic or polymorphonuclear MDSCs (PMN-MDSCs) are similar to neutrophils, while monocytic MDSCs (M-MDSCs) are similar to monocytes. A third, less common population of MDSCs has been described in humans, which is called early-stage MDSCs.The role of these cells is more complex in autoimmune diseases. Recently, numerical, phenotypical, and functional differences in MDSCs were demonstrated in patients with RRMS and SPMS [246].

Patients with SPMS had a decreased frequency of M-MDSCs and PMN-MDSCs compared with healthy controls, while the frequency of M-MDSCs and PMN-MDSCs was increased in patients with RRMS during relapse as compared with healthy controls. More importantly, M-MDSCs demonstrated the capacity to suppress T cells in patients with RRMS and healthy controls, while these cells promoted autologous T cell proliferation in patients with SPMS [246]. In EAE, the preventive and therapeutic administration of purified antigen-presenting MDSCs led to lower percentages of activated T cells and higher percentages of regulatory B cells, which implied that MDSCs had tolerogenic properties [247]. More research into MS is needed before MDSCs can be investigated as a therapeutic cell product in human clinical trials.

2.6 Utilization of Cells as Carriers of Antigens to Induce Tolerance

2.6.1. Peripheral Blood Mononuclear Cells

An alternative methodology for effective immunosuppression in the treatment of autoimmune diseases includes the coupling of self-antigen-derived peptides to cellular vehicles utilizing chemical fixatives [248]. The induction of immunosuppression utilizing this strategy is indirect and implies that the fixed cells quickly go through apoptotic cell death following fixation and consequently continue intact peptides to tolerogenic APCs for processing and presentation [249,250]. Lutterotti et al., played out an open-label, single-center, dose raising stage I/IIa study to assess the restorative utilization of autologous peripheral blood mononuclear cells (PBMCs) in nine patients with MS: two patients had SPMS and seven patients had RRMS. The PBMCs were combined with seven myelin-determined peptides that were related with MS pathogenesis and against which evident reactions could be identified in the patients included in the preliminary [251].

2.6.2. Erythrocytes

Erythrocytes, which are otherwise called red cells (RBCs), are the most widely recognized type of blood cell. Their main role is to deliver oxygen to body tissues. RBCs are ceaselessly cleared from circulation through phagocytosis without getting an autoimmune system reaction. Thus, the tolerogenic properties of these apoptotic cells can be utilized to design tolerance-inducing RBCs. Pishesha et al., depicted one such method, called sortagging, sortase-mediated transpeptidation [252]. Engineered RBCs that were covalently connected to MOG35-55 protect against and turn around early signs of EAE [252]. A phase Ib clinical preliminary including this approach began recruiting patients with MS in October 2017 [253]. Results were introduced as a late-breaking abstract during ECTRIMS 2019. The examiners detailed that there was a decrease in antigen-specific T cell reactions to myelin peptides in the high-dose group, while the extent of type 1 regulatory T cell (Tr1) and nTregs, and IL-10 levels expanded giving proof of immune tolerance prompted by this treatment procedure.

3. Main points of contention While Designing Cell-Based Treatments For MS

3.1 Autologous Versus Allogeneic Treatment

Cell items for tolerance induction can be gotten from a similar individual (autologous) or another individual (allogeneic). According to a commonsense perspective, there are many benefits related with the utilization of allogeneic cell treatment. For example, allogeneic cell treatment has a lower creation cost contrasted with the expense related with individualized autologous cell items. There is likewise a higher accessibility of allogeneic cell items on the grounds that cryopreserved stocks can be utilized, and that implies that they are accessible as off-the-shelf items [254]. Notwithstanding, the risk of host immune rejection because of GVHD (Graft versus host disease) is significant in allogeneic cell treatment and requires major areas of strength for immune suppression to permit cell engraftment for immune modulatory purposes. Autoimmune system patients are probably not going to go through similar heavy lymphodepletion as patients with malignant growth, which makes it much harder to evade the immune system with an allogeneic item. Conversely, the risk is negligible in autologous treatment. Furthermore, donor screening is a much stricter for allogeneic cell treatment with regards to infectious screening, for example, for (human leukocyte antigens) HLA composing, which brings about inflated costs [254]. Furthermore, on the grounds that most patients with autoimmune diseases don't have a similar urgency to start cell treatment as patients with cancer, aside from a life-threatening, the advantages of an autologous patient-specific cell treatment item might offset the advantages of off-the-shelf treatment in the autoimmune setting. Given these issues, autologous treatment is many times liked over allogeneic treatment for tolerance induction, and its long term persistence could legitimize its high cost tag. For instance, both European and American rules don't suggest allogeneic HSCT in patients with MS [255,256]. Besides, likewise allogeneic Treg treatment has just been tried in immunosuppressed and immunocompromised individuals [117]. Regardless, future plan of more widespread cell-based treatments might actually result from more information and research utilizing CRISPR-Cas9 innovation to deliver cells HLA deficient or to initiate the ectopic expression of non-canonical HLA-E or HLA-G genes, which are expressed during maternal-fetal tolerance [119].

3.2 Antigen-Specificity

General immune modulation might be joined by undesired side effects, like opportunistic infections and secondary autoimmunity. In this way, bridling the immune system to reestablish immune tolerance prompting tolerance inducing cell systems requires loading the cell item with myelin antigens or receptors, depending upon the cell type utilized, to get disease related antigen specificity.Despite the fact that substitutes just 15-30% of all out-myelin content [257], the myelin proteins are presumed to be the major antigenic focuses of the MS-driving autoimmune reaction [258]. The protein content inside the myelin sheath is prevalently made out of proteolipid protein and MBP, as well as other myelin proteins, for example, MOG [257]. Regardless of their abundance in the myelin sheath, epitopes from these three myelin proteins have been demonstrated to be encephalitogenic in various animal models [259]. Hence, the reactivity towards a wide variety of myelin peptides can be distinguished in patients with MS [260,261]. Guiding myelin particularity to cell-based treatments for MS might address a promising way to deal with tackle MS-related autoimmunity. Along these lines, the dysregulated myelin-coordinated insusceptible reaction could be reestablished, without influencing the ordinary surveillance and effector capability of the immune system. Few clinical preliminaries have researched myelin-specific cell-based treatments. For sure, large numbers of the previously mentioned cell medicines don't have a myelin-specific method of activity, albeit empowering safety results have been shown for a several antigen-specific treatment approaches in stage I and II clinical preliminaries for MS [262,263,264,265].

Different traps have restricted the advancement of antigen-specific treatment. To start with, despite the fact that myelin proteins are proposed to be culprit antigens, no single antigenic target has been distinguished. Myelin reactivity in patients with MS is heterogeneous and potentially dynamic as a result of the development of neo-autoreactivities because of disease reactivity related tissue damage, which is related with epitope spreading [266,267,268]. In this manner, there is no obvious single peptide or peptide mix at which tolerance reconstitution can be pointed. Additionally, despite the fact that ex vivo reactivity can be coordinated towards a wide assortment of myelin peptides, some are non-pathogenic, for example, the cryptic mysterious or not naturally processed epitopes [269]. These factors entangle the selection of targets for antigen-specific treatment. In any case, few side effects were accounted for in clinical preliminaries with antigen-specific treatments [270]. Nonetheless, a risk of prompting MS exacerbation or

hypersensitivity responses while attempting to regulate the immune system in a myelin-specific way remains. In this unique situation, the administration of myelin antigens through carrier cells could address a more controlled way to deal with prompt stable and antigen-specific immune tolerance.A several imaginative antigen-specific treatment systems are at present in the preclinical stage and may address a portion of the recently referenced issues. New antigen-loading procedures are being explored as options in contrast to traditional peptide pulsing. For example, transfection with viral vectors or nucleic acids encoding full-length myelin proteins might prompt the introduction of a wide assortment of normally processed myelin peptides. These new systems could be utilized to build the viability of current cell-based antigen-specific treatment approaches, as well as to add antigen-specificity to cell treatments that are not yet explicitly coordinated towards the myelin reaction, including MSC-, HSC-and Treg-based procedures. These new methodologies might address a fascinating an open door for antigen-specific cell treatment.

3.3 Migration Across the Blood-Brain Barrier

The dealing of cell-based treatments into the CNS can be utilized for designated immunotherapy against different neuroinflammatory diseases [271,272,273,274]. To be sure, the triumph of cell-based immunotherapy in inducing immune tolerance relies upon the precise conveyance and trafficking of the therapeutic, i.e., tolerance inducing cells, to the inflammatory sites [275,276]. Consequently, a clear comprehension of the fundamental systems engaged with cell migration is important to propel the improvement of new treatments. In any case, section into the CNS is vigorously limited by the blood-brain barrier (BBB), a diffusion barrier that firmly regulates homeostasis of the CNS and blocks the influx of most compounds from the blood to the cerebrum [277,278,279]. The restrictive nature of the BBB gives an impediment to medicate conveyance to the CNS. In spite of the fact that there have been clinical advances with cerebrum and CNS diseases, the treatment of these problems stays testing and lacking in light of the BBB, which keeps many medications available for use from arriving at the mind. Thus, significant endeavors have been made in creating techniques ready to balance or sidestep the BBB for conveyance of therapeutics [280].

In any case, a few of cell types, including MSCs, Tregs and DCs, can migrate all through the BBB effectively, and BBB-trans migratory capacity of the cells could be exploited for the healing centering of the inflammatory disease system in the CNS. Due to their ease of isolation, established safety, and capacity to target various pathways in neuronal regeneration [281,282,283], these cells have also become appealing therapeutic agents and are capable of producing a variety of cytokines and development factors with neuroprotective, safe, and immune modulatory properties [273,284].They express a variety of leukocyte-like homing particles, such as grip particles and chemokine receptors [285,286,287]. They can be used as vehicles to convey antitumor therapeutics for brain tumor treatment and progressing reports have shown the way that they can impart and move across the BBB under injury or inflammation. They use a multistep homing cascade (rolling, bonding, and transmigration) to join endothelial cells [288,289,290].These cells, without a doubt, migrate through the endothelial boundary using adhesion molecules, such as vascular cell adhesion molecule (VCAM)-1 and β1 integrin [291,292]. They specifically migrate on TNF-enacted endothelium rather than naïve endothelium. several chemokine receptors and their ligands, including CXCL9, CXCL16, CCL20 and CCL25, are known to be explicitly drawn in with the cell transmigration through the endothelial layer [281,291,292,293,294].

Although these cells typically undergo a similar migratory cascade to cross the BBB and reach the CNS, they actually require distinct systems for their mode of action. MSCs, for instance, use G-protein-coupled receptor signaling (GPCR-) subordinate pathways to migrate through endothelial cells [281]. MSCs move through distinct holes or pores in the endothelial monolayer that are better for VCAM-1 (transitional cups) by paracellular or transcellular diapedesis. Their migration lacks massive lateral crawling rather than leukocytes, possibly due to the absence of Macintosh 1 expression [285]. Additionally, Tregs frequently cross the endothelium of the cerebrum to suppress the effects of effector lymphocytes at the site of inflammation. Continuous assessments have suggested that the area of low numbers of Tregs in the CNS of patients with MS [295,296,297] and murine Tregs showed augmented migratory capacity in vitro and in vivo through the BBB [300,301]. Similarly, human FoxP3+ Tregs move more rapidly than other cells across the in vitro human cerebrum endothelium. Under non-inflammatory conditions, tregs from patients with RRMS demonstrated impaired migratory capacities [289].

Insusceptible cells use the integrin CD62L as an urgent lymphoid homing particle, and Tregs use it as a significant relocation-related particle [298]. Unmistakable signals from chemokines and chemokine receptors, such as CCR7 and CCR6, limit the temporary limit of Tregs through the BBB [292]. In addition, DCs in the central nervous system (CNS) are associated with illness severity and exhibit more productive immigration than white blood cells in in vitro models of the BBB [271]. The provocative relocation of DCs is linked to a variety of chemokine receptors and ligands, including CCR5 [299], and as a result, these receptors and ligands ought to be targeted for the development of treatments. Crossing the BBB is a fundamental for this huge number of cells to apply their supportive effects in treating neurological diseases or CNS injury and is major for their usage as vehicles for drug transport to treat mind malignant growths. As a result, it would be beneficial in the long run to focus specifically on the sale and division of these phone models into various locations in order to implement their appropriate safe concealment. As a result, efforts have been made to construct the CNS transitory limit of cells, such as tolDC electroporation of CCR5-encoding mRNA. In a similar vein, in an in vitro model of the BBB, the ability of mRNA-electroporated tolDCs to migrate toward a chemokine slope significantly increased, but neither the tolerogenic aggregate nor the lymphocyte stimulatory capacity of tolDCs was affected [300].

Additionally, the ability to screen the development and fate of these cells under in vivo conditions is valuable in imagining prudent supportive frameworks and is similarly essential for development of these methods. In vivo bioluminescence imaging and other painless in vivo cell following techniques are utilized in this regard [301]. This is a roundabout cell stamping technique with writer characteristics which grants cell continuing in little animal models. In vivo bioluminescence imaging columnist quality methods can also be used to effectively check the adaptability of cells, such as MSCs, DCs, and Tregs, to the target tissue [302,303,304]. In the ongoing and upcoming clinical investigations, it is necessary to zero in on the utilization of various useful methodologies that exploit the relocation-related particles for various cell types [305,306,307]. The vast majority of current clinical assessments use intradermal or subcutaneous courses of association with different outcomes [308,309]. The impact of the organization course on the proficiency of the remedial vaccination remains unclear and a topic of discussion in light of these reports. The general immunization result is anticipated to improve with additional streamlining.

II. Conclusion

As a result of advances in understanding MS's pathogenesis and course, remarkable progress has been made in its treatment. Relapsing infections and central nervous system inflammation are now closely under close and complete control thanks to the development of highly effective treatments. However, since current treatments only partially protect against the neurodegenerative aspect of MS, effective treatment of movement remains a neglected need. Even though studies of the patient's history suggest that the disease has significantly progressed during treatment, more clinical and real evaluations are expected to gather long-term efficacy and safety evidence for these treatments. As we strive to develop evidence-based and tailored approaches to MS treatment and managment, additional investigations into the value of highly effective agents for early treatment and patient protection will also be essential.

Conflict Of Interest

All authors declare no conflicts of interest.

Authors Contribution

Authors have equally participated and shared every item of the work.

References

[1]- Kasper, Dennis, et al. *Harrison's principles of internal medicine, 19e*. Vol. 1. No. 2. New York, NY, USA: McGraw-Hill, 2015.

[2]- Browne, Paul, et al. "Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity." *Neurology* 83.11 (2014): 1022-1024.

[3]- Lublin, Fred D., et al. "Defining the clinical course of multiple sclerosis: the 2013 revisions." *Neurology* 83.3 (2014): 278-286.

[4]- Feigin, Valery L., et al. "Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016." *The Lancet Neurology* 18.5 (2019): 459-480.

[5]- Kamm, Christian P., Bernard M. Uitdehaag, and Chris H. Polman. "Multiple sclerosis: current knowledge and future outlook." *European neurology* 72.3-4 (2014): 132-141.

[6]- Confavreux, Christian, and Sandra Vukusic. "Natural history of multiple sclerosis: a unifying concept." *Brain* 129.3 (2006): 606-616.

[7]- Wallin, Mitchell T., et al. "The prevalence of MS in the United States: a population-based estimate using health claims data." *Neurology* 92.10 (2019): e1029-e1040.

[8]- Cree, B., J. A. Hollenbach, and R. Bove. "a. C., et al. 2019. Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis." *Ann Neurol*.

[9]- Kappos, Ludwig, et al. "Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study." *Multiple Sclerosis Journal* 24.7 (2018): 963-973.

[10]-Hauser, Stephen L., and Bruce AC Cree. "Treatment of multiple sclerosis: a review." *The American journal of medicine*133.12 (2020): 1380-1390.

[11]-Thompson, Alan J., et al. "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria." *The Lancet Neurology* 17.2 (2018): 162-173.

[12]-Filippi, Massimo, et al. "MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines." *The Lancet Neurology* 15.3 (2016): 292-303.

[13]-Hauser, Stephen L., et al. "Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis." *New England Journal of Medicine* 376.3 (2017): 221-234.

[14]-Montalban, Xavier, et al. "Ocrelizumab versus placebo in primary progressive multiple sclerosis." *New England Journal of Medicine* 376.3 (2017): 209-220.

[15]-Hauser, Stephen L., et al. "Ofatumumab versus teriflunomide in multiple sclerosis." *New England Journal of Medicine* 383.6 (2020): 546-557.

[16]- Polman, Chris H., et al. "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis." *New England Journal of Medicine* 354.9 (2006): 899-910.

[17]- Coles, Alasdair J., et al. "Alemtuzumab vs. interferon beta-1a in early multiple sclerosis." *N Engl J Med* 359.17 (2008): 1786-1801.

[18]- Cohen, Jeffrey A., et al. "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial." *The Lancet* 380.9856 (2012): 1819-1828.

[19]- Cohen, Jeffrey A., et al. "Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial." *The Lancet* 380.9856 (2012): 1819-1828.

[20]- Goodin, D. S., et al. "The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology." *Neurology* 61.10 (2003): 1332-1338.

[21]- Montalban, Xavier, et al. "Ocrelizumab versus placebo in primary progressive multiple sclerosis." *New England Journal of Medicine* 376.3 (2017): 209-220.

[22]- Kappos, Ludwig, et al. "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis." *New England Journal of Medicine* 362.5 (2010): 387-401.

[23]- Kappos, Ludwig, et al. "Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study." *The Lancet* 391.10127 (2018): 1263-1273.

[24]- Comi, Giancarlo, et al. "Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicenter, randomised, minimum 12-month, phase 3 trial." *The Lancet Neurology* 18.11 (2019): 1009-1020.

[25]- Cohen, Jeffrey A., et al. "Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicenter, randomised, 24-month, phase 3 trial." *The Lancet Neurology* 18.11 (2019): 1021-1033.

[26]- Fox, Robert J., et al. "Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis." *New England Journal of Medicine* 367.12 (2012): 1087-1097.

[27]- Gold, Ralf, et al. "Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis." *New England Journal of Medicine* 367.12 (2012): 1098-1107.

[28]- Giovanni, Gavin, et al. "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis." *New England Journal of Medicine* 362.5 (2010): 416-426.

[29]- O'Connor, Paul, et al. "Randomized trial of oral teriflunomide for relapsing multiple sclerosis." *New England Journal of Medicine* 365.14 (2011): 1293-1303. [31]-Giovannoni, Gavin, et al. "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis." *New England Journal of Medicine* 362.5 (2010): 416-426.

[30]- Kappos, Ludwig, et al. "Fingolimod in relapsing multiple sclerosis: an integrated analysis of safety findings." *Multiple sclerosis and related disorders* 3.4 (2014): 494-504.

[31]- Ebers, George C. "Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis." *The Lancet* 352.9139 (1998): 1498-1504

[32]- Jacobs, Lawrence D., et al. "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis." *Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society* 39.3 (1996): 285-294.

[33]- Calabresi, Peter A., et al. "Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study." *The Lancet Neurology* 13.7 (2014): 657-665.

[34]- IFNB Multiple Sclerosis Study Group. "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial." *Neurology* 43.4 (1993): 655-655.

[35]-Nakajima, Hideaki. "Guest editorial: Hematopoietic stem cells." *International Journal of Hematology* 106 (2017): 16-17.

[36]-Blank, Norbert, et al. "Low-dose cyclophosphamide effectively mobilizes peripheral blood stem cells in patients with autoimmune disease." *European journal of haematology* 97.1 (2016): 78-82.

[37]-Salvino, Marco Aurélio, and Jefferson Ruiz. "Hematopoietic progenitor cell mobilization for autologous transplantation-a literature review." *Revista Brasileira de Hematologia e Hemoterapia* 38 (2016): 28-36.

[38]-Hübel, Kai. "Mobilization and Collection of HSC." *The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies* (2019): 117-122.

[39]-Sharrack, Basil, et al. "Autologous hematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (JACIE)." *Bone marrow transplantation* 55.2 (2020): 283-306.

[40]-Mancardi, Gianluigi, et al. "Intense immunosuppression followed by autologous hematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis." *Multiple Sclerosis Journal* 24.3 (2018): 245-255.

[41]-Muraro, Paolo A., et al. "Autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis." *Nature Reviews Neurology* 13.7 (2017): 391-405.

[42]-Burman, Joachim, et al. "Autologous hematopoietic stem cell transplantation for neurological diseases." *Journal of Neurology, Neurosurgery & Psychiatry* 89.2 (2018): 147-155.

[43]-Sormani, Maria Pia, et al. "Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis." *Neurology* 88.22 (2017): 2115-2122.

[44]-Boffa, Giacomo, et al. "Long-term clinical outcomes of hematopoietic stem cell transplantation in multiple sclerosis." *Neurology* 96.8 (2021): e1215-e1226.

[45]-Sboha, W. "Vård vid Multipel Skleros och Parkinsons Sjukdo." *Socialstyrelsen: Falun, Sweden* (2016): 26-30.

[46] Laureys, Guy, et al. "A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis." *Acta Neurologica Belgica* 118 (2018): 161-168.

[47]-Zephir, Helene, et al. "Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis." *Bulletin du Cancer* 106.1S (2018): S92-S101.

[48]-Cohen, Jeffrey A., et al. "Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American Society for Blood and Marrow Transplantation." *Biology of Blood and Marrow Transplantation* 25.5 (2019): 845-854.

[49]-Bowen, James D., et al. "Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results." *Bone marrow transplantation* 47.7 (2012): 946-951.

[50]-Curro', Daniela, et al. "Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: a MRI-based clinical study." *Multiple Sclerosis Journal* 21.11 (2015): 1423-1430.

[51]-Mancardi, Giovanni L., et al. "Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial." *Neurology* 84.10 (2015): 981-988.

[52]-Burman, Joachim, et al. "Autologous hematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience." *Journal of Neurology, Neurosurgery & Psychiatry* 85.10 (2014): 1116-1121.

[53]-Atkins, Harold L., et al. "Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicenter single-group phase 2 trial." *The Lancet* 388.10044 (2016): 576-585.

[54]-Nash, Richard A., et al. "High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS." *Neurology* 88.9 (2017): 842-852.

[55]-Burt, Richard K., et al. "Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study." *The Lancet Neurology* 8.3 (2009): 244-253.

[56]-Burt, Richard K., et al. "Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis: a randomized clinical trial." *Jama* 321.2 (2019): 165-174.

[57]-Zhukovsky, Christina, et al. "Autologous hematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study." *Journal of Neurology, Neurosurgery & Psychiatry* 92.2 (2021): 189-194.

[58]-Harris, Kristina M., et al. "Extensive intrathecal T cell renewal following hematopoietic transplantation for multiple sclerosis." *JCI insight* 5.2 (2020).

[59]-Arruda, Lucas CM, et al. "Immunological correlates of favorable long-term clinical outcome in multiple sclerosis patients after autologous hematopoietic stem cell transplantation." *Clinical Immunology* 169 (2016): 47-57.

[60]-Muraro, Paolo A., et al. "T cell repertoire following autologous stem cell transplantation for multiple sclerosis." *The Journal of clinical investigation* 124.3 (2014): 1168-1172.

[61]-Abrahamsson, Sofia V., et al. "Non-myeloablative autologous hematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis." *Brain* 136.9 (2013): 2888-2903.

[62]-Darlington, Peter J., et al. "Natural killer cells regulate Th17 cells after autologous hematopoietic stem cell transplantation for relapsing remitting multiple sclerosis." *Frontiers in immunology* 9 (2018): 834.

[63]-Darlington, Peter J., et al. "Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation." *Annals of neurology* 73.3 (2013): 341-354.

[64]-Sousa, Alessandra de Paula A., et al. "Autologous hematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis." *Clinical science* 128.2 (2015): 111-120

[65]- Larsson, Diane, et al. "Intrathecal immunoglobulins and neurofilament light after autologous hematopoietic stem cell transplantation for multiple sclerosis." *Multiple Sclerosis Journal* 26.11 (2020): 1351-1359.

[66]- Bertolotto, Antonio, et al. "Autologous hematopoietic stem cell transplantation (AHSCT): standard of care for relapsing–remitting multiple sclerosis patients." *Neurology and Therapy* 9 (2020): 197-203.

[67]- Hendrawan, Kevin, et al. "Tolerance regeneration by T regulatory cells in autologous hematopoietic stem cell transplantation for autoimmune diseases." *Bone Marrow Transplantation* 55.5 (2020): 857-866.

[68]- Friedenstein, Alexander J., et al. "Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues: cloning in vitro and retransplantation in vivo." *Transplantation* 17.4 (1974): 331-340.

[69]- Marigo, Ilaria, and Francesco Dazzi. "The immunomodulatory properties of mesenchymal stem cells." *Seminars in immunopathology*. Vol. 33. Springer-Verlag, 2011.

[70]-Di Nicola, Massimo, et al. "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli." *Blood, The Journal of the American Society of Hematology* 99.10 (2002): 3838-3843.

[71]-Meisel, Roland, et al. "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase–mediated tryptophan degradation." *Blood* 103.12 (2004): 4619-4621.

[72]-Sato, Kazuya, et al. "Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells." *Blood* 109.1 (2007): 228-234.

[73]-Batten, Puspa, et al. "Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves." *Tissue engineering* 12.8 (2006): 2263-2273.

[74]-Aggarwal, Sudeepta, and Mark F. Pittenger. "Human mesenchymal stem cells modulate allogeneic immune cell responses." *Blood* 105.4 (2005): 1815-1822.

[75]-Augello, Andrea, et al. "Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway." *European journal of immunology* 35.5 (2005): 1482-1490.

[76]-Beyth, Shaul, et al. "Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness." *Blood* 105.5 (2005): 2214-2219.

[77]-Prevosto, Claudia, et al. "Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction." *haematologica* 92.7 (2007): 881-888.

[78]-Haniffa, Muzlifah A., et al. "Adult human fibroblasts are potent immunoregulatory cells and functionally equivalent to mesenchymal stem cells." *The Journal of Immunology* 179.3 (2007): 1595-1604.

[79]-Zhou, Heping, et al. "Mesenchymal stem cells might be used to induce tolerance in heart transplantation." *Medical hypotheses* 70.4 (2008): 785-787.

[80]-Rasmusson, Ida, et al. "Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes." *Journal of Leucocyte Biology* 82.4 (2007): 887-893.

[81]-Sotiropoulou, Panagiota A., et al. "Interactions between human mesenchymal stem cells and natural killer cells." *Stem cells* 24.1 (2006): 74-85.

[82]-Spaggiari, Grazia Maria, et al. "Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation." *Blood* 107.4 (2006): 1484-1490.

[83]-Maccario, Rita, et al. "Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype." *Haematologica* 90.4 (2005): 516-525.

[84]-Zappia, Emanuela, et al. "Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy." *Blood* 106.5 (2005): 1755-1761.

[85]-DiGirolamo, Carla M., et al. "Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate." *British journal of haematology* 107.2 (1999): 275-281.

[86]-Sekiya, Ichiro, et al. "Expansion of human adult stem cells from bone marrow stroma: conditions that maximize the yields of early progenitors and evaluate their quality." *Stem cells* 20.6 (2002): 530-541.

[87]-Hagh, Majid Farshdousti, et al. "Feasibility of cell therapy in multiple sclerosis: a systematic review of 83 studies." *International journal of hematology-oncology and stem cell research* 7.1 (2013): 15.

[88]-Llufriu, Sara, et al. "Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis." *PloS one* 9.12 (2014): e113936.

[89]-Zhang, Jing, et al. "Bone marrow stromal cells reduce axonal loss in experimental autoimmune encephalomyelitis mice." *Journal of neuroscience research* 84.3 (2006): 587-595.

[90]-Bai, Lianhua, et al. "Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis." *Glia* 57.11 (2009): 1192-1203.

[91]-Wilkins, Alastair, et al. "Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro." *Stem cell research* 3.1 (2009): 63-70.

[92]-Li, Dongjie, et al. "Human umbilical cord-derived mesenchymal stem cells differentiate into epidermal-like cells using a novel co-culture technique." *Cytotechnology* 66 (2014): 699-708.

[93]-Kopen, Gene C., Darwin J. Prockop, and Donald G. Phinney. "Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains." *Proceedings of the National Academy of Sciences* 96.19 (1999): 10711-10716.

[94]-Arvey, Aaron, et al. "Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells." *Nature immunology* 15.6 (2014): 580-587.

[95]-Ohkura, Naganari, Yohko Kitagawa, and Shimon Sakaguchi. "Development and maintenance of regulatory T cells." *Immunity* 38.3 (2013): 414-423.

[96]-Samstein, Robert M., et al. "Foxp3 exploits a pre-existent enhancer landscape for regulatory T cell lineage specification." *Cell* 151.1 (2012): 153-166.

[97]-Liu, Weihong, et al. "CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells." *The Journal of experimental medicine* 203.7 (2006): 1701-1711.

[98]-de Lafaille, Maria A. Curotto, and Juan J. Lafaille. "Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor?." *Immunity* 30.5 (2009): 626-635.

[99]-Josefowicz, Steven Z., et al. "Extrathymically generated regulatory T cells control mucosal TH2 inflammation." *Nature* 482.7385 (2012): 395-399.

[100]-Mason, Gavin M., et al. "Phenotypic complexity of the human regulatory T cell compartment revealed by mass cytometry." *The Journal of Immunology* 195.5 (2015): 2030-2037.

[101]-Apostolou, Irina, et al. "Peripherally induced Treg: mode, stability, and role in specific tolerance." *Journal of clinical immunology* 28 (2008): 619-624.

[102]-Sakaguchi, Shimon. "Regulatory T cells: key controllers of immunologic self-tolerance." *Cell* 101.5 (2000): 455-458.

[103]-Ehrenstein, Michael R., et al. "Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy." *The Journal of experimental medicine* 200.3 (2004): 277-285.

[104]-Lindley, Shelley, et al. "Defective suppressor function in CD4+ CD25+ T-cells from patients with type 1 diabetes." *Diabetes* 54.1 (2005): 92-99.

[105]-Sugiyama, Hideaki, et al. "Dysfunctional blood and target tissue CD4+ CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation." *The Journal of Immunology* 174.1 (2005): 164-173.

[106]-Balandina, Anna, et al. "Functional defect of regulatory CD4+ CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis." *Blood* 105.2 (2005): 735-741.

[107]-Kriegel, Martin A., et al. "Defective suppressor function of human CD4+ CD25+ regulatory T cells in autoimmune polyglandular syndrome type II." *The Journal of experimental medicine* 199.9 (2004): 1285-1291.

[108]-Kohm, Adam P., et al. "Cutting edge: CD4+ CD25+ regulatory T cells suppress antigen-specific autoreactive immune responses and central nervous system inflammation during active experimental autoimmune encephalomyelitis." *The Journal of Immunology* 169.9 (2002): 4712-4716.

[109]-Tanaka, Hajime, et al. "Successful immunotherapy of autoimmune cholangitis by adoptive transfer of fork head box protein 3+ regulatory T cells." *Clinical & Experimental Immunology* 178.2 (2014): 253-261.

[110]-Edinger, Matthias. "Regulatory T cells for the prevention of graft-versus-host disease: Professionals defeat amateurs." *European journal of immunology* 39.11 (2009): 2966-2968.

[111]-Trenado, Aurélie, et al. "Ex vivo-expanded CD4+ CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells." *The Journal of Immunology* 176.2 (2006): 1266-1273.

[112]-Xiao, Fang, et al. "Ex vivo expanded human regulatory T cells delay islet allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2rγnull mice." *PloS one* 9.3 (2014): e90387.

[113]-Sagoo, Pervinder, et al. "Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells." *Science translational medicine* 3.83 (2011): 83ra42-83ra42.

[114]-Epstein, David J., Jeffrey Dunn, and Stan Deresinski. "Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management." *Open forum infectious diseases*. Vol. 5. No. 8. US: Oxford University Press, 2018.

[115]-Jonuleit, Helmut, et al. "Infectious tolerance: human CD25+ regulatory T cells convey suppressor activity to conventional CD4+ T helper cells." *The Journal of experimental medicine* 196.2 (2002): 255-260.

[116]-Thornton, Angela M., and Ethan M. Shevach. "Suppressor effector function of CD4+ CD25+ immunoregulatory T cells is antigen nonspecific." *The Journal of Immunology* 164.1 (2000): 183-190.

[117]-MacDonald, K. N., J. M. Piret, and M. K. Levings. "Methods to manufacture regulatory T cells for cell therapy." *Clinical & Experimental Immunology* 197.1 (2019): 52-63.

[118]-Seay, Howard R., et al. "Expansion of human Tregs from cryopreserved umbilical cord blood for GMP-compliant autologous adoptive cell transfer therapy." *Molecular Therapy-Methods & Clinical Development* 4 (2017): 178-191.

[119]-Raffin, Caroline, Linda T. Vo, and Jeffrey A. Bluestone. "Treg cell-based therapies: challenges and perspectives." *Nature Reviews Immunology* 20.3 (2020): 158-172.

[120]-Safinia, Niloufar, et al. "Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation." *Oncotarget* 7.7 (2016): 7563.

[121]-Thomson, Angus W., Hēth R. Turnquist, and Giorgio Raimondi. "Immunoregulatory functions of mTOR inhibition." *Nature Reviews Immunology* 9.5 (2009): 324-337.

[122]-Battaglia, Manuela, et al. "Rapamycin promotes expansion of functional CD4+ CD25+ FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients." *The Journal of Immunology* 177.12 (2006): 8338-8347.

[123]-Mathew, James M., et al. "A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants." *Scientific reports* 8.1 (2018): 7428.

[124]-Schiavinato, Josiane Lilian dos Santos, et al. "TGF-beta/atRA-induced Tregs express a selected set of microRNAs involved in the repression of transcripts related to Th17 differentiation." *Scientific reports* 7.1 (2017): 3627.

[125]-Scottà, Cristiano, et al. "Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+ CD25+ FOXP3+ T regulatory cell subpopulations." *Haematologica* 98.8 (2013): 1291.

[126]-Esensten, Jonathan H., et al. "Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: the next frontier." *Journal of Allergy and Clinical Immunology* 142.6 (2018): 1710-1718.

[127]-Chwojnicki, Kamil, et al. "Administration of CD4+ CD25 high CD127− FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study." *BioDrugs* 35 (2021): 47-60.

[128]-Romano, Marco, et al. "Past, present, and future of regulatory T cell therapy in transplantation and autoimmunity." *Frontiers in immunology* 10 (2019): 43.

[129]-Marek-Trzonkowska, Natalia, et al. "Therapy of type 1 diabetes with CD4+ CD25highCD127-regulatory T cells prolongs survival of pancreatic islets—Results of one-year follow-up." *Clinical immunology* 153.1 (2014): 23-30.

[130]-Morgan, Mary E., et al. "Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells." *Arthritis & Rheumatism* 52.7 (2005): 2212-2221.

[131]-Mottet, Christian, Holm H. Uhlig, and Fiona Powrie. "Cutting edge: cure of colitis by CD4+ CD25+ regulatory T cells." *The Journal of Immunology* 170.8 (2003): 3939-3943.

[132]-Brunstein, Claudio G., et al. "Adoptive Transfer of Umbilical Cord Blood-Derived Regulatory T Cells Increases Early Viral Reactivation." *Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation* 19.8 (2013).

[133]-Green, E. Allison, Yongwon Choi, and Richard A. Flavell. "Pancreatic lymph node-derived CD4+ CD25+ Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals." *Immunity* 16.2 (2002): 183-191.

[134]-Tang, Qizhi, et al. "In vitro–expanded antigen-specific regulatory T cells suppress autoimmune diabetes." *The Journal of experimental medicine* 199.11 (2004): 1455-1465.

[135]-Tarbell, Kristin V., et al. "CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes." *The Journal of experimental medicine* 199.11 (2004): 1467-1477.

[136]-Masteller, Emma L., et al. "Expansion of functional endogenous antigen-specific CD4+ CD25+ regulatory T cells from nonobese diabetic mice." *The Journal of immunology* 175.5 (2005): 3053-3059.

[137]-Tarbell, Kristin V., et al. "Dendritic cell–expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice." *The Journal of experimental medicine* 204.1 (2007): 191-201.

[138]-Ferreira, Leonardo MR, et al. "Next-generation regulatory T cell therapy." *Nature reviews Drug discovery* 18.10 (2019): 749-769.

[139]-Mekala, Divya J., and Terrence L. Geiger. "Immunotherapy of autoimmune encephalomyelitis with redirected CD4+ CD25+ T lymphocytes." *Blood* 105.5 (2005): 2090-2092.

[140]-Mekala, Divya J., Rajshekhar S. Alli, and Terrence L. Geiger. "IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+ CD25+ T lymphocytes." *Proceedings of the National Academy of Sciences* 102.33 (2005): 11817-11822.

[141]-Kim, Yong Chan, et al. "Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells." *Journal of autoimmunity* 92 (2018): 77-86.

[142]-Allan, Sarah E., et al. "Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3." *Molecular Therapy* 16.1 (2008): 194-202.

[143]-Aarts-Riemens, Tineke, et al. "Forced overexpression of either of the two-common human Foxp3 isoforms can induce regulatory T cells from CD4+ CD25–cells." *European journal of immunology* 38.5 (2008): 1381-1390.

[144]-Fransson, Moa, et al. "CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery." *Journal of neuroinflammation* 9 (2012): 1-12.

[145]-Pohl, Alessandra De Paula, et al. "Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression." *Cellular Immunology* 358 (2020): 104222.

[146]-Granucci, F., I. Zanoni, and P. Ricciardi-Castagnoli. "Central role of dendritic cells in the regulation and deregulation of immune responses." *Cellular and Molecular Life Sciences* 65 (2008): 1683-1697.

[147]-Steinman, Ralph M. "Dendritic cells: versatile controllers of the immune system." *Nature medicine* 13.10 (2007): 1155-1159.

[148]-Van Brussel, Ilse, Zwi N. Berneman, and Nathalie Cools. "Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system." *Mediators of inflammation* 2012 (2012).

[149]-Banchereau, Jacques, et al. "Immunobiology of dendritic cells." *Annual review of immunology* 18.1 (2000): 767-811.

[150]-Banchereau, Jacques, and Ralph M. Steinman. "Dendritic cells and the control of immunity." *Nature* 392.6673 (1998): 245-252.

[151]-Boltjes, Arjan, and Femke Van Wijk. "Human dendritic cell functional specialization in steady-state and inflammation." *Frontiers in immunology* 5 (2014): 131.

[152]-Moser, Muriel. "Dendritic cells in immunity and tolerance—do they display opposite functions?." *Immunity* 19.1 (2003): 5-8.

[153]-Thewissen, Kristof, et al. "Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors." *Multiple sclerosis journal* 20.5 (2014): 548-557.

[154]-Huang, Y. M., et al. "Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-β and IL-10." *Clinical & Experimental Immunology* 124.2 (2001): 306-314.

[155]-Karni, Arnon, et al. "Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response." *The Journal of Immunology* 177.6 (2006): 4196-4202.

[156]-Huang, Yu-Min, et al. "Dendritic cells derived from patients with multiple sclerosis show high CD1a and low CD86 expression." *Multiple Sclerosis Journal* 7.2 (2001): 95-99.

[157]-Vaknin-Dembinsky, Adi, Konstantin Balashov, and Howard L. Weiner. "IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production." *The Journal of Immunology* 176.12 (2006): 7768-7774.

[158]-Vaknin-Dembinsky, Adi, et al. "Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis." *Journal of neuroimmunology* 195.1-2 (2008): 140-145.

[159]-Nuyts, Amber H., et al. "Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies?" *Multiple Sclerosis Journal* 19.8 (2013): 995-1002.

[160]-Van Brussel, Ilse, et al. "Tolerogenic dendritic cell vaccines to treat autoimmune diseases: can the unattainable dream turn into reality?" *Autoimmunity reviews* 13.2 (2014): 138-150.

[161]-Tkachenko, Nataliya, et al. "Generation of dendritic cells from human peripheral blood monocytes-comparison of different culture media." *Folia Histochemica et Cytobiologica* 43.1 (2005): 25-30.

[162]-Hackstein, Holger, and Angus W. Thomson. "Dendritic cells: emerging pharmacological targets of immunosuppressive drugs." *Nature Reviews Immunology* 4.1 (2004): 24-35.

[163]-van Kooten, Cees, et al. "Dendritic cells as a tool to induce transplantation tolerance: obstacles and opportunities." *Transplantation* 91.1 (2011): 2-7.

[164]-Flórez-Grau, Georgina, et al. "Tolerogenic dendritic cells as a promising antigen-specific therapy in the treatment of multiple sclerosis and neuromyelitis optica from preclinical to clinical trials." *Frontiers in immunology* 9 (2018): 1169.

[165]-Kalantari, Tahereh, et al. "Generation of immunogenic and tolerogenic clinical-grade dendritic cells." *Immunologic research* 51 (2011): 153-160.

[166]-García-González, Paulina, et al. "A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines." *Journal of translational medicine* 11 (2013): 1-15.

[167]-Naranjo-Gómez, Mar, et al. "Comparative study of clinical grade human tolerogenic dendritic cells." *Journal of translational medicine* 9.1 (2011): 1-14.

[168]-Adorini, Luciano, et al. "Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands." *The Journal of steroid biochemistry and molecular biology* 89 (2004): 437-441.

[169]-Penna, Giuseppe, et al. "Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+ Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3." *Blood* 106.10 (2005): 3490-3497.

[170]-Adorini, Luciano, et al. "Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands." *The Journal of steroid biochemistry and molecular biology* 89 (2004): 437-441.

[171]-Pedersen, A. W., et al. "Phenotypic and functional markers for 1α, 25-dihydroxyvitamin D3-modified regulatory dendritic cells." *Clinical & Experimental Immunology* 157.1 (2009): 48-59.

[172]-Széles, Lajos, et al. "1, 25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype." *The Journal of Immunology* 182.4 (2009): 2074-2083.

[173]-Ferreira, Gabriela Bomfim, et al. "Differential protein pathways in 1, 25-dihydroxyvitamin D3 and dexamethasone modulated tolerogenic human dendritic cells." *Journal of proteome research* 11.2 (2012): 941-971.

[174]-Raïch-Regué, Dàlia, et al. "Differential effects of monophosphoryl lipid A and cytokine cocktail as maturation stimuli of immunogenic and tolerogenic dendritic cells for immunotherapy." *Vaccine* 30.2 (2012): 378-387.

[175]-Raïch-Regué, Dàlia, et al. "Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients." *European journal of immunology* 42.3 (2012): 771-782.

[176]-Ferreira, Gabriela Bomfim, et al. "Vitamin D3 induces tolerance in human dendritic cells by activation of intracellular metabolic pathways." *Cell reports* 10.5 (2015): 711-725.

[177]-Malaguarnera, L., et al. "Vitamin D3 regulates LAMP3 expression in monocyte derived dendritic cells." *Cellular Immunology* 311 (2017): 13-21.

[178]-Lee, Wai-Ping, et al. "Immunomodulatory Effects of 1, 25-Dihydroxyvitamin D 3 on Dendritic Cells Promote Induction of T Cell Hypo responsiveness to Myelin-Derived Antigens." *Journal of Immunology Research* 2016 (2016).

[179]-Navarro-Barriuso, Juan, et al. "MAP7 and MUCL1 are biomarkers of Vitamin D3-induced tolerogenic dendritic cells in multiple sclerosis patients." *Frontiers in immunology* 10 (2019): 1251.

[180]-Farias, Alessandro S., et al. "Vitamin D3 Induces IDO+ Tolerogenic DC s and Enhances Treg, Reducing the Severity of EAE." *CNS neuroscience & therapeutics* 19.4 (2013): 269-277.

[181]-Mansilla, María José, et al. "Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis." *CNS neuroscience & therapeutics* 21.3 (2015): 222-230.

[182]-Mansilla, María José, et al. "Cryopreserved vitamin D 3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients." *Journal of neuroinflammation* 13 (2016): 1-11.

[183]-Tacken, Paul J., et al. "Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting." *Nature Reviews Immunology* 7.10 (2007): 790-802.

[184]-Unger, Wendy WJ, and Yvette van Kooyk. "'Dressed for success' C-type lectin receptors for the delivery of glyco-vaccines to dendritic cells." *Current opinion in immunology* 23.1 (2011): 131-137.

[185]-Ponsaerts, P., V. F. I. Van Tendeloo, and Z. N. Berneman. "Cancer immunotherapy using RNA-loaded dendritic cells." *Clinical & Experimental Immunology* 134.3 (2003): 378-384.

[186]-Boudreau, Jeanette E., et al. "Engineering dendritic cells to enhance cancer immunotherapy." *Molecular therapy* 19.5 (2011): 841-853.

[187]-Shurin, Michael R., et al. "Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?" *Expert Opinion on Biological Therapy* 10.11 (2010): 1539-1553.

[188]-Cathelin, Dominique, et al. "Dendritic cell–tumor cell hybrids and immunotherapy: what's next?" *Cytotherapy* 13.7 (2011): 774-785.

[189]-Koido, Shigeo, et al. "Cancer immunotherapy by fusions of dendritic cells and tumor cells." (2009): 49-62.

[190]-Connolly, Nancy C., et al. "Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals." *Clinical and Vaccine Immunology* 15.2 (2008): 284-292.

[191]-Brody, J. D., and E. G. Engleman. "DC-based cancer vaccines: lessons from clinical trials." *Cytotherapy* 6.2 (2004): 122-127.

[192]-Van Tendeloo, Viggo FI, et al. "Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells." *Blood, The Journal of the American Society of Hematology* 98.1 (2001): 49-56.

[193]-Boczkowski, David, et al. "Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo." *The Journal of experimental medicine* 184.2 (1996): 465-472.

[194]-Kavanagh, Daniel G., et al. "Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm-or lysosome-targeted Nef." *Blood* 107.5 (2006): 1963-1969.

[195]-Melhem, Nada M., et al. "Robust CD4+ and CD8+ T cell responses to SIV using mRNA-transfected DC expressing autologous viral Ag." *European Journal of Immunology* 37.8 (2007): 2164-2173.

[196]-Sæbøe-Larssen, Stein, Ellen Fossberg, and Gustav Gaudernack. "mRNA-based electro transfection of human dendritic cells and induction of cytotoxic T lymphocyte responses against the telomerase catalytic subunit (hTERT)." *Journal of immunological methods* 259.1-2 (2002): 191-203.

[197]-Strobel, I., et al. "Human dendritic cells transfected with either RNA or DNA encoding influenza matrix protein M1 differ in their ability to stimulate cytotoxic T lymphocytes." *Gene therapy* 7.23 (2000): 2028-2035.

[198]-Steinman, Ralph M., and Jacques Banchereau. "Taking dendritic cells into medicine." *Nature* 449.7161 (2007): 419-426.

[199]-Cabezón, Raquel, and Daniel Benítez-Ribas. "Therapeutic potential of tolerogenic dendritic cells in IBD: from animal models to clinical application." *Clinical and developmental immunology* 2013 (2013).

[200]-Wculek, Stefanie K., et al. "Dendritic cells in cancer immunology and immunotherapy." *Nature Reviews Immunology* 20.1 (2020): 7-24.

[201]-Santos, Patricia M., and Lisa H. Butterfield. "Dendritic cell–based cancer vaccines." *The Journal of Immunology* 200.2 (2018): 443-449.

[202]-Giannoukakis, Nick, et al. "Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients." *Diabetes care* 34.9 (2011): 2026-2032.

[203]-Benham, Helen, et al. "Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype–positive rheumatoid arthritis patients." *Science translational medicine* 7.290 (2015): 290ra87-290ra87.

[204]-Jauregui-Amezaga, Aranzazu, et al. "Intraperitoneal administration of autologous tolerogenic dendritic cells for refractory Crohn's disease: a phase I study." *Journal of Crohn's and Colitis* 9.12 (2015): 1071-1078.

[205]-Suwandi, Jessica S., et al. "Inducing tissue specific tolerance in autoimmune disease with tolerogenic dendritic cells." *Clin Exp Rheumatol* 33.4 Suppl 92 (2015): 97-103.

[206]-Bell, G. M., et al. "Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis." *Annals of the rheumatic diseases* 76.1 (2017): 227-234.

[207]-Zarkhin, Valeriya, et al. "Characterization of intra-graft B cells during renal allograft rejection." *Kidney international* 74.5 (2008): 664-673.

[208]-Zarkhin, Valeriya, Geetha Chalasani, and Minnie M. Sarwal. "The yin and yang of B cells in graft rejection and tolerance." *Transplantation reviews* 24.2 (2010): 67-78.

[209]-Barnas, Jennifer L., Richard John Looney, and Jennifer H. Anolik. "B cell targeted therapies in autoimmune disease." *Current opinion in immunology* 61 (2019): 92-99.

[210]-Li, Rui, Kristina R. Patterson, and Amit Bar-Or. "Reassessing B cell contributions in multiple sclerosis." *Nature immunology* 19.7 (2018): 696-707.

[211]-Iwata, Yohei, et al. "Characterization of a rare IL-10–competent B-cell subset in humans that parallels mouse regulatory B10 cells." *Blood, The Journal of the American Society of Hematology* 117.2 (2011): 530-541.

[212]-DiLillo, David J., Takashi Matsushita, and Thomas F. Tedder. "B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer." *Annals of the New York Academy of Sciences* 1183.1 (2010): 38-57.

[213]-Sun, Jia-Bin, Cecil Czerkinsky, and Jan Holmgren. "B lymphocytes treated in vitro with antigen coupled to cholera toxin B subunit induce antigen-specific Foxp3+ regulatory T cells and protect against experimental autoimmune encephalomyelitis." *The Journal of Immunology* 188.4 (2012): 1686-1697.

[214]-Su, Yan, et al. "B cells "transduced" with TAT-fusion proteins can induce tolerance and protect mice from diabetes and EAE." *Clinical Immunology* 140.3 (2011): 260-267.

[215]-Pennati, Andrea, et al. "Regulatory B cells induce formation of IL-10-expressing T cells in mice with autoimmune neuroinflammation." *Journal of Neuroscience* 36.50 (2016): 12598-12610.

[216]-Zhang, Ai-Hong, et al. "B-cell delivered gene therapy for tolerance induction: role of autoantigen-specific B cells." *Journal of autoimmunity* 35.2 (2010): 107-113.

[217]-Calderón-Gómez, Elisabeth, et al. "Reprogrammed quiescent B cells provide an effective cellular therapy against chronic experimental autoimmune encephalomyelitis." *European journal of immunology* 41.6 (2011): 1696-1708.

[218]-Yanaba, Koichi, et al. "A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses." *Immunity* 28.5 (2008): 639-650.

[219]-Matsushita, Takashi, et al. "Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression." *The Journal of clinical investigation* 118.10 (2008): 3420-3430.

[220]-Pennati, Andrea, et al. "Regulatory B cells normalize CNS myeloid cell content in a mouse model of multiple sclerosis and promote oligodendrogenesis and remyelination." *Journal of Neuroscience* 40.26 (2020): 5105-5115.

[221]-Caligiuri, Michael A. "Human natural killer cells." *Blood, The Journal of the American Society of Hematology* 112.3 (2008): 461-469.

[222]-Freud, Aharon G., et al. "The broad spectrum of human natural killer cell diversity." *Immunity* 47.5 (2017): 820-833.

[223]-Vivier, Eric, et al. "Functions of natural killer cells." *Nature immunology* 9.5 (2008): 503-510.

[224]-Gianchecchi, Elena, Domenico Vittorio Delfino, and Alessandra Fierabracci. "NK cells in autoimmune diseases: Linking innate and adaptive immune responses." *Autoimmunity Reviews* 17.2 (2018): 142-154.

[225[-Mimpen, Max, et al. "Natural killer cells in multiple sclerosis: a review." *Immunology letters* 222 (2020): 1-11.

[226]-Netea, Mihai G., Jessica Quintin, and Jos WM Van Der Meer. "Trained immunity: a memory for innate host defense." *Cell host & microbe* 9.5 (2011): 355-361.

[227]-Cohan, Stanley L., et al. "Daclizumab: mechanisms of action, therapeutic efficacy, adverse events and its uncovering the potential role of innate immune system recruitment as a treatment strategy for relapsing multiple sclerosis." *Biomedicines* 7.1 (2019): 18.

[228]-Luessi, Felix, et al. "GFAPα IgG-associated encephalitis upon daclizumab treatment of MS." *Neurology-Neuroimmunology Neuroinflammation* 5.5 (2018).

[229]-Gold, Ralf, et al. "Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial." *The Lancet* 381.9884 (2013): 2167-2175.

[230]-Kappos, Ludwig, et al. "Daclizumab HYP versus interferon beta-1a in relapsing multiple sclerosis." *New England Journal of Medicine* 373.15 (2015): 1418-1428.

[231]-Lancet, The. "End of the road for daclizumab in multiple sclerosis." *Lancet (London, England)* 391.10125 (2018): 1000.

[232]-Shimasaki, Noriko, Amit Jain, and Dario Campana. "NK cells for cancer immunotherapy." *Nature reviews Drug discovery* 19.3 (2020): 200-218.

[233]-Fang, Fang, Weihua Xiao, and Zhigang Tian. "NK cell-based immunotherapy for cancer." *Seminars in immunology*. Vol. 31. Academic Press, 2017.

[234]-Hegde, Subramanya, et al. "Autoreactive natural killer T cells: promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells." *Immunology* 130.4 (2010): 471-483.

[235]-Pratschke, Johann, Diana Stauch, and Katja Kotsch. "Role of NK and NKT cells in solid organ transplantation." *Transplant International* 22.9 (2009): 859-868.

[236]-Wu, Lan, and Luc V. Kaer. "Natural killer T cells and autoimmune disease." *Current molecular medicine* 9.1 (2009): 4-14.

[237]-Kriegsmann, Katharina, et al. "NKT cells—New players in CAR cell immunotherapy?" *European journal of haematology* 101.6 (2018): 750-757.

[238]-Sakuishi, Kaori, Sachiko Miyake, and Takashi Yamamura. "Role of NK cells and invariant NKT cells in multiple sclerosis." *Molecular Basis of Multiple Sclerosis: The Immune System* (2010): 127-147.

[239]-Van Kaer, Luc, and Lan Wu. "Therapeutic potential of invariant natural killer T cells in autoimmunity." *Frontiers in immunology* 9 (2018): 519.

[240]-Van Kaer, Luc, Lan Wu, and Vrajesh V. Parekh. "Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis." *Immunology* 146.1 (2015): 1-10.

[241]-Exley, Mark A., S. Brian Wilson, and Steven P. Balk. "Isolation and functional use of human NKT cells." *Current protocols in immunology* 119.1 (2017): 14-11.

[242]-Ma, Huijuan, and Chang-Qing Xia. "Phenotypic and functional diversities of myeloid-derived suppressor cells in autoimmune diseases." *Mediators of Inflammation* 2018 (2018).

[243]-Wegner, Anja, Johan Verhagen, and David C. Wraith. "Myeloid-derived suppressor cells mediate tolerance induction in autoimmune disease." *Immunology* 151.1 (2017): 26-42.

[244]-Veglia, Filippo, Michela Perego, and Dmitry Gabrilovich. "Myeloid-derived suppressor cells coming of age." *Nature immunology* 19.2 (2018): 108-119.

[245]-Bronte, Vincenzo, et al. "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards." *Nature communications* 7.1 (2016): 12150.

[246]- Iacobaeus, Ellen, et al. "Phenotypic and functional alterations of myeloid-derived suppressor cells during the disease course of multiple sclerosis." *Immunology and Cell Biology* 96.8 (2018): 820-830.

[247]- Steinman, Ralph M. "Dendritic cells: versatile controllers of the immune system." *Nature medicine* 13.10 (2007): 1155-1159.

[248]- Miller, Stephen D., Danielle M. Turley, and Joseph R. Podojil. "Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease." *Nature Reviews Immunology* 7.9 (2007): 665-677.

[249]- Smith, Cassandra E., and Stephen D. Miller. "Multi-peptide coupled-cell tolerance ameliorates ongoing relapsing EAE associated with multiple pathogenic autoreactivities." *Journal of autoimmunity* 27.4 (2006): 218-231.

[250]- Turley, Danielle M., and Stephen D. Miller. "Peripheral tolerance induction using ethylene carbodiimide-fixed APCs uses both direct and indirect mechanisms of antigen presentation for prevention of experimental autoimmune encephalomyelitis." *The Journal of Immunology* 178.4 (2007): 2212-2220.

[251]- Lutterotti, Andreas, Mireia Sospedra, and Roland Martin. "Antigen-specific therapies in MS—Current concepts and novel approaches." *Journal of the neurological sciences* 274.1-2 (2008): 18-22.

[252]- Pishesha, Novalia, et al. "Engineered erythrocytes covalently linked to antigenic peptides can protect against autoimmune disease." *Proceedings of the National Academy of Sciences* 114.12 (2017): 3157-3162.

[253]- Lutterotti, A., et al. "Establish tolerance in MS with myelin-peptide coupled red blood cells-ETIMS (red) trial." *MULTIPLE SCLEROSIS JOURNAL*. Vol. 24. 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND: SAGE PUBLICATIONS LTD, 2018.

[254]- Malik, Nafees. "Allogeneic versus autologous stem-cell therapy." *BioPharm International* 25.7 (2012).

[255]- Snowden, J. A., et al. "Hematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation." *Bone marrow transplantation* 47.6 (2012): 770-790.

[256]- Majhail, Navneet S., et al. "Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation." *Biology of Blood and Marrow Transplantation* 21.11 (2015): 1863-1869.

[257]- Quarles, R. H., W. B. Macklin, and P. Morell. "Basic neurochemistry: molecular, cellular and medical aspects." *Myelin formation, structure and biochemistry. Elsevier Science* (2006).

[258]- Hohlfeld, Reinhard, et al. "The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets." *The Lancet Neurology* 15.2 (2016): 198-209.

[259]- Rangachari, Manu, and Vijay K. Kuchroo. "Using EAE to better understand principles of immune function and autoimmune pathology." *Journal of autoimmunity* 45 (2013): 31-39.

[260]- Greer, Judith M. "Autoimmune T-cell reactivity to myelin proteolipids and glycolipids in multiple sclerosis." *Multiple sclerosis international* 2013 (2013).

[261]- Sáez-Torres, Irene, et al. "Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse." *Autoimmunity* 35.1 (2002): 45-50.

[262]- Sáez-Torres, Irene, et al. "Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse." *Autoimmunity* 35.1 (2002): 45-50.

[263]- Walczak, Agata, et al. "Transdermal application of myelin peptides in multiple sclerosis treatment." *JAMA neurology* 70.9 (2013): 1105-1109.

[264]- Warren, K. G., and Ingrid Catz. "Administration of myelin basic protein synthetic peptides to multiple sclerosis patients." *Journal of the neurological sciences* 133.1-2 (1995): 85-94.

[265]- Weiner, Howard L., et al. "Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis." *Science* 259.5099 (1993): 1321-1324.

[266]- Goebels, Norbert, et al. "Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence." *Brain* 123.3 (2000): 508-518.

[267]- Tuohy, Vincent K., and R. Philip Kinkel. "Epitope spreading: a mechanism for progression of autoimmune disease." *ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS-ENGLISH EDITION*- 48.5 (2000): 347-352.

[268]- Tuohy, Vincent K., et al. "The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis." *Immunological reviews* 164.1 (1998): 93-100.

[269]- Anderton, Stephen M., et al. "Influence of a dominant cryptic epitope on autoimmune T cell tolerance." *Nature immunology* 3.2 (2002): 175-181.

[270]- Kappos, Ludwig, et al. "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis." *New England Journal of Medicine* 362.5 (2010): 387-401.

[271]- Sallusto, Federica, and Antonio Lanzavecchia. "The instructive role of dendritic cells on T-cell responses." *Arthritis Research & Therapy* 4.3 (2002): 1-6.

[272]- Steinman, Ralph M. "Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation." *The Mount Sinai journal of medicine, New York* 68.3 (2001): 160-166.

[273]- Sagar, Divya, et al. "Mechanisms of dendritic cell trafficking across the blood–brain barrier." *Journal of Neuroimmune Pharmacology* 7 (2012): 74-94.

[274]- Pinheiro, Melissa A. Lopes, et al. "Immune cell trafficking across the barriers of the central nervous system in multiple sclerosis and stroke." *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 1862.3 (2016): 461-471.

[275]- Sabado, Rachel L., Sreekumar Balan, and Nina Bhardwaj. "Dendritic cell-based immunotherapy." *Cell research* 27.1 (2017): 74-95.

[276]- Mohammad, Mohammad G., et al. "Dendritic cells and multiple sclerosis: disease, tolerance and therapy." *International journal of molecular sciences* 14.1 (2012): 547-562.

[277]- Ballabh, Praveen, Alex Braun, and Maiken Nedergaard. "The blood–brain barrier: an overview: structure, regulation, and clinical implications." *Neurobiology of disease* 16.1 (2004): 1-13.

[278]- De Vries, Helga E., et al. "The blood-brain barrier in neuroinflammatory diseases." *Pharmacological reviews* 49.2 (1997): 143-156.

[279]- Pardridge, William M. "The blood-brain barrier: bottleneck in brain drug development." *NeuroRx* 2 (2005): 3-14.

[280]- He, Quanguo, et al. "Towards improvements for penetrating the blood–brain barrier—recent progress from a material and pharmaceutical perspective." *Cells* 7.4 (2018): 24.

[281]- Teo, Grace SL, et al. "Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms." *Stem cells* 30.11 (2012): 2472-2486.

[282]- Colton, Carol A. "Immune heterogeneity in neuroinflammation: dendritic cells in the brain." *Journal of Neuroimmune Pharmacology* 8 (2013): 145-162.

[283]- Ukena, Sya N., et al. "Isolation strategies of regulatory T cells for clinical trials: phenotype, function, stability, and expansion capacity." *Experimental hematology* 39.12 (2011): 1152-1160.

[284]- Rice, Claire M., et al. "Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases." *The Lancet* 382.9899 (2013): 1204-1213.

[285]- Teo, Grace SL, et al. "Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-α-activated endothelial cells via both leukocyte-like and novel mechanisms." *Stem cells* 30.11 (2012): 2472-2486.

[286]- Sonar, Sandip Ashok, and Girdhari Lal. "Differentiation and transmigration of CD4 T cells in neuroinflammation and autoimmunity." *Frontiers in immunology* 8 (2017): 1695.

[287]- Meena, Megha, and Nathalie Cools. "On the road to new treatments for multiple sclerosis: Targeting dendritic cell migration into the central nervous system." *Neural Regeneration Research* 14.12 (2019): 2088.

[288]- Matsushita, Takashi, et al. "Mesenchymal stem cells transmigrate across brain microvascular endothelial cell monolayers through transiently formed inter-endothelial gaps." *Neuroscience letters* 502.1 (2011): 41-45.

[289]- Schneider-Hohendorf, Tilman, et al. "Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis." *European journal of immunology* 40.12 (2010): 3581-3590.

[290]- Takeshita, Yukio, and Richard M. Ransohoff. "Inflammatory cell trafficking across the blood–brain barrier: chemokine regulation and in vitro models." *Immunological reviews* 248.1 (2012): 228-239.

[291]- Chamberlain, Giselle, et al. "Mesenchymal stem cells exhibit firm adhesion, crawling, spreading and transmigration across aortic endothelial cells: effects of chemokines and shear." *PloS one* 6.9 (2011): e25663.

[292]- Ding, Yaozhong, Jiangnan Xu, and Jonathan S. Bromberg. "Regulatory T cell migration during an immune response." *Trends in immunology* 33.4 (2012): 174-180.

[293]- Engelhardt, Britta, and Richard M. Ransohoff. "Capture, crawl, cross: the T cell code to breach the blood–brain barriers." *Trends in immunology* 33.12 (2012): 579-589.

[294]- Worbs, Tim, Swantje I. Hammerschmidt, and Reinhold Förster. "Dendritic cell migration in health and disease." *Nature Reviews Immunology* 17.1 (2017): 30-48.

[295]- Feger, U., et al. "Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients." *Clinical & Experimental Immunology* 147.3 (2007): 412-418.

[296]- Zozulya, Alla L., and Heinz Wiendl. "The role of regulatory T cells in multiple sclerosis." *Nature clinical practice Neurology* 4.7 (2008): 384-398.

[297]- Michel, Laure, et al. "Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor α-chain are excluded from the analysis." *The Journal of clinical investigation* 118.10 (2008): 3411-3419.

[298]- Wei, Shuang, Ilona Kryczek, and Weiping Zou. "Regulatory T-cell compartmentalization and trafficking." *Blood* 108.2 (2006): 426-431.

[299]- Tiberio, Laura, et al. "Chemokine and chemotactic signals in dendritic cell migration." *Cellular & molecular immunology* 15.4 (2018): 346-352.

[300]- De Laere, Maxime, et al. "Shuttling tolerogenic dendritic cells across the blood–brain barrier in vitro via the introduction of de novo C–C chemokine receptor 5 expression using messenger RNA electroporation." *Frontiers in Immunology* 8 (2018): 1964.

[301]- Kim, Jung Eun, Senthilkumar Kalimuthu, and Byeong-Cheol Ahn. "In vivo cell tracking with bioluminescence imaging." *Nuclear Medicine and Molecular Imaging* 49 (2015): 3-10.

[302]- Wang, Hui, et al. "Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging." *Stem cells* 27.7 (2009): 1548-1558.

[303]- Kleinovink, Jan Willem, et al. "A dual-color bioluminescence reporter mouse for simultaneous in vivo imaging of T cell localization and function." *Frontiers in immunology* 9 (2019): 3097.

[304]- Maes, Wim, et al. "In vivo bioluminescence imaging in an experimental mouse model for dendritic cell-based immunotherapy against malignant glioma." *Journal of neuro-oncology* 91 (2009): 127-139.

[305]- Ben-Hur, Tamir. "Cell therapy for multiple sclerosis." *Neurotherapeutics* 8.4 (2011): 625-642.

[306]- Høglund, Rune A., et al. "A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate (GA)." *PLoS One* 8.4 (2013): e62237.

[307]- Kivisäkk, Pia, et al. "Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis." *PLoS One* 9.7 (2014): e103716.

[308]- Quillien, Véronique, et al. "Biodistribution of radiolabeled human dendritic cells injected by various routes." *European journal of nuclear medicine and molecular imaging* 32 (2005): 731-741.

[309]- Lesterhuis, W. Joost, et al. "Route of administration modulates the induction of dendritic cell vaccine–induced antigen-specific T Cells in advanced melanoma patients." *Clinical Cancer Research* 17.17 (2011): 5725-5735.